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(57) 	 ABSTRACT 
A new fractionation device shows desirable features for 
exploratory screening and biomarker discovery. The constitu-
ent MSCs may be tailored for desired pore sizes and surface 
properties and for the sequestration and enrichment of 
extremely low abundant protein and peptides in desired 
ranges of the mass/charge spectrum. The MSCs are effective 
in yielding reproducible extracts from complex biological 
samples as small as 10 ltl in a time as short as 30 minutes. 
They are inexpensive to manufacture, and allow for scaled up 
production to attain the simultaneous processing of a large 
number of samples. The MSCs are multiplexed, label-free 
diagnostic tools with the potential of biological recognition 
moiety modification for enhanced specificity. The MSCs may 
store, protect and stabilize biological fluids, enabling the 
simplified and cost-effective collection and transportation of 
clinical samples. The MSC-based device may serve as a diag-
nostic tool to complement histopathology, imaging, and other 
conventional clinical techniques. The MSCs mediated iden-
tification of disease-specific protein signatures may help in 
the selection of personalized therapeutic combinations, in the 
real-time assessment of therapeutic efficacy and toxicity, and 
in the rational modulation of therapy based on the changes in 
the protein networks associated with the prognosis and the 
drug resistance of the disease. 
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WAFER PORE VOLUME NL POROSITY (%) THICKNESS (NM) COPOLYMER TREATMENT 
X1 5.82 46 393 F127+30%TMB 
X2 8.02 48.9 510 F127 
X3 8.02 48.9 510 F127 
X4 8.02 48.9 510 F127 
X5 10.31 60 534 L64 
X6 9 53.1 527 L121 +TFTS 
X7 9.02 53.2 527 L121 02 PLASMA 
X8 9.89 51.5 597 L64+50%PPG 
X9 12.94 60.3 667 L121 +50%PPG 02 PLASMA 
X10 11.86 57 647 P123+50%PPG 02 PLASMA 
X11 11 57.2 598 L121 +100%PPG 02 PLASMA 
X12 13.45 62.6 668 L121 +150%PPG 02 PLASMA 
X13 7.327 44.8 508 L121 +50%TMB 
X14 1 	 10.59 52.35 629 L121 +50%MPTES 
X15 5.09 30.9 512 L121 +50%MPTES 
NX1 9.98 53.3 582 L64 
NX2 10.56 53.9 609 L64 02 PLASMA 
NX5 9.98 53.3 582 L64 HMDS 
NX3 1 	 8.95 52.8 527 F108 02 PLASMA 
NX4 7.85 54.2 450 F108 HMDS 
NT1 8.59 42.2 633 F127 
NT2 12.13 48.9 771 F127 
NT3 7.19 37.4 598 F127 
NT4 4.66 42.6 340 P123 
NT5 1 	 15.09 62.3 753 L121 +50%PPG 
NT6 13.23 62.7 656 L121 +100%PPG 
NT7 7.86 60.3 405 L121 +150%PPG 
NT8 8.62 57.4 467 L121 
NT9 1 	 7.84 1 	 44 1 	 554 1 	 P123 APTES 
FIG. 21 
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BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The subject matter described in this application relates 
generally to the field of nanotechnology and, in particular, to 
porous, nanoporous, and mesoporous objects, such as par-
ticles, and methods for fractionation, stabilization, and stor-
age of biomolecules. 
2. Background of the Invention 
A promising strategy of early disease diagnosis is the 
detection of molecular biomarkers from readily available 
body fluids, such as blood. Considerable attention has been 
devoted to the development of proteomic methods for the 
quantitative and simultaneous detection and identification of 
molecular biomarkers constituted by multiple proteins and 
peptides using Mass Spectrometry (MS). Several strategies of 
sample treatment prior to MS analysis have been developed 
including conventional 2-dimensional gel electrophoresis, 
pre-fractionation processes, depletion of most abundant pro-
teins, and beads equalization. In spite of these advances, less 
effort has been made to overcome the problems of denatur-
ation and degradation of samples during long sample han-
dling procedures, maintenance of protein stability during 
sample processing, and stabilization of samples during long-
term storage. Furthermore, the detection of low abundant 
markers and low molecular weight (LMW) species remains a 
critical challenge due to experimental variability, limited 
reproducibility, long sample handling procedures, protein 
stability during sample processing, and generation of mis-
leading artifacts as a consequence of unreliable experimental 
procedures. Macrostructure materials have been used to 
address some of these issues, and continue to be potentially 
useful in many applications. 
SUMMARY OF THE INVENTION 
A first of numerous aspects of the invention is to provide a 
method of fractionating or separating components in a sample 
comprising the steps of providing a sample comprising at 
least a first component and a second component; providing a 
substrate comprising a mesoporous material having two or 
more domains, wherein the two or more domains allow for 
separation of the first and second component; and contacting 
the mesoporous material with the sample to separate the first 
component and second component. 
It is a further aspect of the invention to provide a method of 
separating components in a biological sample, the method 
2 
comprising the steps of providing a biological sample having 
a first component and a second component; providing a sub-
strate comprising a mesoporous material with a pre-deter-
mined pore morphology, wherein said pore morphology per- 
m mits the separation of the first component from said second 
component; and contacting the biological sample with said 
substrate to separate the first component and second compo-
nent. 
It is a further aspect of the invention to provide the method 
io as described above wherein the sample is a biological fluid 
selected from the group consisting of blood serum, blood 
plasma, blood, urine, seminal fluid, seminal plasma, pleural 
fluid, ascites, nipple aspirate, feces, and saliva. 
It is a further aspect of the invention to provide the method 
15 as described above wherein the first component and the sec-
ond component comprise peptides, antigens, antibodies, pro-
teins, protein fragments, RNA, or DNA, and a molecular 
weight of the first component is lower than a molecular 
weight of the second component. 
20 	 It is a further aspect of the invention to provide the method 
as described above further comprising stabilizing the first and 
second components that have been separated into domains. 
It is a further aspect of the invention to provide the method 
as described above wherein the mesoporous material is a 
25 nanoporous silicon, nanoporous oxide material, and/or nan-
oporous silica. 
It is a further aspect of the invention to provide the method 
as described above wherein the mesoporous material is a 
molecular cut-off. The molecular cut-off of the substrate of 
30 the present invention may range from 700 Da to 50 kDa, 
optionally from I kDa to 25 kDa, optionally from 10 kDa to 
15 kDa. 
It is a further aspect of the invention to provide the method 
as described above wherein the two or more domains on the 
35 mesoporous material have different modified surfaces, said 
modified surface differing in terms of molecular cut-off, pore 
structure, electrical charge, and/or functionalization with 
organic functional groups or inorganic metal ions, or both. 
Organic functional groups contemplated by the present 
40 invention include, but are not limited to, amino, thiol, carboxy 
acid, sulfate, phosphate, and epoxy moieties. Inorganic metal 
ions contemplated by the present invention include, but are 
not limited to, gallium, titanium, or zirconium. 
It is a further aspect of the invention to provide the method 
45 as described above wherein said two or more domains are 
defined on the mesoporous material by photolithography 
compatible photoresists, molded PDMS films, or silicone 
rubbers. 
It is a further aspect of the invention to provide the method 
5o as described above wherein the substrate is selected from the 
group consisting of a film, a wafer, a particle, and a microchip. 
It is a further aspect of the invention to provide the method 
as described above further comprising extracting the first 
component from the mesoporous material, washing the 
55 mesoporous material subsequent to said contacting the meso-
porous material with the sample, and wherein one domain on 
the mesoporous material adsorbs the first component. 
It is a further aspect of the invention to provide the method 
as described above further comprising analyzing the first 
60 component by mass spectrometry, gel electrophoresis, chro-
matography, bioassay, or a combination thereof, wherein the 
mass spectrometry is MALDI-TOF mass spectrometry, 
LC/MS mass spectrometry, ESI-MS mass spectrometry, tan-
dem mass-spectrometry, or SELDI mass spectrometry. 
65 It is a further aspect of the invention to provide a method of 
analyzing a sample, the method comprising the steps of pro-
viding the sample; providing a substrate comprising a meso- 
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porous material comprising two or more domains; exposing 
the mesoporous material to the sample such that a fraction of 
the sample is retained by the mesoporous material; and ana-
lyzing said fraction of the sample retained by the mesoporous 
material. 5 
It is a further aspect of the invention to provide a method of 
detecting a marker of a physiological condition in a sample, 
the method comprising the steps of providing a sample 
affected by the physiological condition; providing a substrate 
comprising a mesoporous material comprising two or more to 
domains; exposing the mesoporous material to the sample; 
analyzing a fraction of the sample retained by a domain on the 
mesoporous material; and comparing a result of the analyzing 
with a result of analyzing a control sample to detect the 15 
marker of the physiological condition. 
It is a further aspect of the invention to provide a probe 
comprising a substrate that comprises a mesoporous material 
comprising two or more domains to separate a first compo-
nent from a second component into said domains, wherein 20 
said probe is configured and arranged to be inserted into a 
mass spectrometer. 
It is a further aspect of the invention to provide the method 
as described above wherein said pre-determined pore mor- 
phology is selected from the group consisting of cubic, hex- 25 
agonal, honeycomb-like, tubular, circular, oblong, and com-
binations thereof. 
It is a further aspect of the invention to provide the method 
as described above wherein the mesoporous material has a 
pore size of 1 mu to 30 mu, optionally 1 nm to 25 nm, 30 
optionally 1 mu to 20 mu, optionally 2 nm to 12 mu, or 
optionally 2 mu to 10 mu. 
It is a further aspect of the invention to provide a method of 
analyzing a sample, the method comprising the steps of pro-
viding the sample; providing a substrate comprising a meso- 35 
porous material, wherein the pores of said mesoporous mate-
rial have a pre-determined pore morphology; exposing the 
mesoporous material to the sample such that a fraction of the 
sample is retained by the mesoporous material; and analyzing 
a fraction of the sample retained by the mesoporous material. 40 
It is a further aspect of the invention to provide a method of 
detecting a marker of a physiological condition in a sample, 
the method comprising the steps of providing a sample 
affected by the physiological condition; providing a substrate 
comprising a mesoporous material, wherein the pores of said 45 
mesoporous material are substantially uniform and have a 
pre-determined pore morphology; exposing the mesoporous 
material to the sample; analyzing a fraction of the sample 
retained by the mesoporous material; and comparing a result 
of the analyzing with a result of analyzing a control sample to 50 
detect the marker of the physiological condition. 
It is a further aspect of the invention to provide a probe 
comprising a substrate that comprises a mesoporous material 
having a pre-determined morphology to separate a first com-
ponent from a second component, wherein said probe is con- 55 
figured and arranged to be inserted into a mass spectrometer. 
It is a further aspect of the invention to provide a mesopo-
rous silica chip comprising multiple pores, and wherein the 
pores on said chip are of different sizes and physiochemical 
properties. 60 
It is a further aspect of the invention to provide the chip as 
described above wherein said physiochemical properties are 
selected from the group consisting of surface area, pore size, 
the presence of organic functional groups or inorganic metal 
ions, and the presence of an electrical charge. 65 
It is a further aspect of the invention to provide the chip as 
described above, wherein said pores have a shape comprising  
4 
2-D or 3-D cubic, 2-D or 3-D hexagonal, honeycomb-like or 
3-D wormlike, tubular, circular, oblong, and combinations 
thereof. 
Still other aspects, features, and attendant advantages of 
the present invention will become apparent to those skilled in 
the art from a reading of the following detailed description of 
embodiments constructed in accordance therewith, taken in 
conjunction with the accompanying figures. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The invention of the present application will now be 
described in more detail with reference to exemplary embodi-
ments of the invention, given only by way of example, and 
with reference to the accompanying drawings, in which: 
FIG.1 is a series ofphotographs ofinesoporous silica chips 
(MSC) patterned either with a 50 µm thick SU-8 hydrophobic 
photoresist (A, C, D) or with a 500 µm thick molded PDMS 
film (B, D, F). In C and D note the relative thickness of the 
different material masks (SU-8 and PDMS, respectively). 
Thetop views of different SU-8 andPDMS patterned chips (E 
and F, respectively) with decreasing fractionation areas show 
the uniformity of the surfaces employed for the sample frac-
tionation. 
FIG. 2 shows the production and assembly of MSCs for 
proteomic applications. Panels A and B show cross-sectional 
views of GX6 chip by SEM and TEM imaging, respectively 
(scale bar is 500 mu). Panel C shows a 45° view of XI chip by 
SEM. Panels D and E show the schematic assembly of silicon 
rubber mask and MSC. Panels F-H are photographs of MSCs 
with the silicone rubber mask; the area defined by the mask 
creates a "well like" structure defined by the thickness of the 
silicone rubber. 
FIG. 3 shows the reproducibility and on-chip stability of 
fractionated serum. Panel a shows MALDI profiles of frac-
tionated serum on X10 chips, which illustrate the increase of 
LMW peptides and proteins detection when the serum is 
processed at 25° C. compared to 4° C. and 37° C. Panels b, c, 
and d show the linear regression analysis of the average 
intensities of detected MS peak for each temperature. The 
comparison was plotted on a log-log scale to create a scatter-
plot. Panel e shows the representative MALDI profiles of 
LMW peptides and proteins eluted immediately after serum 
fractionation or after 3 week on-chip storage at room tem-
perature. Panels f-h show the linear regression analysis of 
average intensities of detected MS peak in each replicate 
compared to replicate 1 for crude, fractionated serum and 
fractionated serum after 3 week storage at room temperature, 
respectively (the coefficient of variation (CV) and the coeffi-
cient of determination (R 2) are indicated in the insets). 
FIG. 4 shows the stability of peptide and protein standards. 
Panels a and b show representative MALDI profiles of the 
LMW and HMW standards, respectively. The stability of the 
set of peptide (16 weight markers from 900 to 8,500 Da) and 
protein (16 weight markers from 3,500 to 66,500 Da) in stock 
solution was investigated by MALDI-TOF MS after 1, 2, 3, 5, 
and 8 days storage at —20° C. 
FIG. 5 is a table showing a summary of the physico-chemi-
cal properties of the selected peptide and protein standards 
and variability of peak intensities for each LMW marker. The 
standards were combined, dispensed in equal amount, dried 
by vacuum centrifugation, and stored at —20° C. The stability 
of the set of standards was investigated by MS, and no deg-
radation was found. The coefficient of variations of the inten-
sities of peaks after 2, 3, 5, and 8 days storage at —20° C. 
compared to freshly prepared sample were calculated (CV2, 
CV3, CV5, and CV8 respectively). 
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FIG. 6 shows the reproducibility of protein fractionation. 
Panel a shows the MALDI profiles in the mass range 900 to 
10000 Da of 6 independently processed replicates of fraction-
ated serum show a highly reproducible peak identity and 
intensity. Panel b the protein recovery from 6 independent 5 
experiments performed with the same chip type using the 
same settings (temperature, time, washings). There is a small 
fluctuation in the amount of protein recovered but there is no 
statistically significant difference among the experiments. 
FIG. 7 shows the production and assembly of MSCs for io 
proteomic applications. Panels a-h show the schematic evo-
lution of the chemical composition of the coating solution 
during the production of a mesoporous silica film. Specifi-
cally, a: Fresh coating solution; b: Formation of micelles; c: 
Evaporation induced self assembly during spin-coating pro- 15 
cess; d: Zoomed in view of a pore after aging at elevated 
temperature. e: Bulk silicon wafer surface; f: Mesoporous 
silica film on a bulk silicon wafer; g: The silicone rubber mask 
was placed above the silica film; h: The final MSC. Panels i 
and j show cross-section views of the GX6 chip obtained by 20 
SEM and TEM imaging respectively (scale bar is 500 mu). 
Panels k,1, and m are photographs of MSCs with the silicone 
rubber mask; the area defined by the mask creates a "well 
like" structure defined by the thickness of the silicone rubber 
(1). Panels n and o show the front and back face of the proto- 25 
type fractionation device assembled with 64 different types of 
MSCs (the scale bar in k-m is 10 mm). 
FIG. 8 shows the physical characterization of selected 
MSCs. Panel a, left side: N2 adsorption-desorption iso-
therms. Panel a, right side: pore size distribution curve. Panel 30 
b shows the reflection SAXS patterns for selected MSCs; 
Panel c shows a representative AFM image of the X11 chip 
structure. 
FIG. 9 shows the principle of MSC fractionation and LMW 
enrichment. Panel a shows that after serum spotting on the 35 
surface, LMW proteins and peptides are trapped into the 
pores while the larger species remained outside the pores and 
are removed during the washing steps. The enriched fractions 
are then eluted and analyzed by MALDI. Panel b shows the 
MALDI profiles of the different steps of the methodology 40 
demonstrate the depletion of most abundant HMW proteins 
in the washings and enrichment of LMW species in the elu-
tion. Panel c shows the comparison of the peptide/Albumin 
ratio, which illustrates the enrichment of LMW peptides 
detected in both serum (in red) and elution (in black). Panel d 45 
shows the comparison of the intensities of Albumin, Apoli-
poprotein Al, and Hemoglobin detected by MS in crude 
serum (in blue) and in the elution (in black). 
FIG. 10 shows the effect of pore sizes and chemical prop-
erties on serum peptide harvesting. Panel a shows a den- 50 
dogram of the unsupervised two-way hierarchical clustering. 
Each set of MSCs is uniquely identified. The dark and light 
blue rectangles represent large and small pores, respectively. 
The green and red rectangles represent the hydrophobic- and 
TMB generated-MSCs, respectively. Panels b-d show super- 55 
vised hierarchical clustering and specific recovery pattern for 
each set of nanochips as indicated in the figure (the complete 
clusters with the mass lists are presented in FIG. 23). The 
relative intensity is gradually indicated with red squares (high 
intensity), black squares (median) and green squares (low 60 
intensity or absence of a peak). Panels e-h show the MS 
profiles of crude serum and purified peptides and proteins 
using a multi-chips strategy. Panel i shows the comparison of 
the number of MS peaks detected in crude serum and after 
fractionation on selected nanochips. The multi-chip strategy 65 
increases more than 3 times the number of non redundant 
LMW peaks detected in serum.  
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FIG. 11 is a table showing a summary of the chemical 
treatments and of the physical properties of the selected 
MSCs used for peptide and protein standard, and serum stud-
ies. 
FIG. 12 shows the physical characterization of the MSC. 
Panel a shows N2 adsorption-desorption isotherms of NX3 
film; the inset shows the pore size distribution derived using 
BJH method. Panel b shows reflection SAXS patterns (in log 
scale) of NX3 film. Panels c and d shows TEM and STEM 
images of NX3 film respectively. Panel e shows reflection 
SAXS patterns (in log scale) of X11 film. 
FIG. 13 shows the TEM imaging of MSC's surface, and 
specifically TEM images of 6 selected MSCs. Note that the 
pore size is increasingly larger from sample GX8 (2.7 mu) to 
X12 (8.9 mu). The scale bar is 10 mu. 
FIG. 14 shows the measurement of surface hydrophobicity 
and hydrophilicity of MSCs. Optical images of 3 representa-
tives contact-angle measurements. The contact angle 
increases with hydrophobicity. 
FIG. 15 shows a standardization curve. Specifically, a rep-
resentative standardization curve is shown made according 
with the instructions provided by the microBCA protein 
assay kit. The graph shows the regression curve that fits the 
experimental results, its formula and its coefficient of deter-
mination (R2). The equation was used to convert the experi-
mental data obtained through Spectrophotometer reading of 
sample absorbance at 562 mu to the corresponding protein 
amount in µg. 
FIG. 16 shows the effect of temperature on protein frac-
tionation. Panel a shows the effect of incubation temperature 
on protein recovery from multiple chips. A set of 5 chips with 
different physical properties were tested at 4° C., 25° C. and 
37° C. In all cases, the amount of protein recovered was 
significantly higher at 25° C. and 37° C. than at 4° C. Panel b 
shows the effect of incubation temperature on the amount of 
protein retained by the chip surface. The amount of protein 
removed through the washing steps was low at 4° C., com-
pared to 25° C. and 37° C. The graph in panel b shows 
representative results obtained using chip X9. Similar results 
were obtained with all the other chips tested (X6, X7, X8, 
X10). 
FIG. 17 shows the effect of incubation time on protein 
fractionation. Panel a shows the total protein recovery after 
fractionation performed at different incubation times. Panel b 
shows a histogram comparing the amount of protein removed 
during the washing steps. In the first wash, the amount of 
protein positively correlated with incubation time. Mean val-
ues and standard deviations of 3 independent experiments are 
shown. Panel c shows the comparison of protein recovery in 
the last 2 washing steps and in the final elution. In all condi-
tions tested, the amount of eluted protein is significantly 
higher than the amount of protein removed from the surface 
during the last 2 washings. 
FIG. 18 shows the MALDI spectra obtained after different 
incubation times. Panel a shows MALDI profiles of fraction-
ated serum on X10 chip at different incubation time (5 min, 15 
min, 30 min, and 60 min). The intensity of peaks detection is 
markedly lower for the min incubation. The profiles for 15 
min, 30 min, and 60 min are similar. Panel b shows the linear 
regression analysis of the triplicate average intensities of 
detected MS peak compared to replicate 1 for each incubation 
time. The comparison was plotted on a log-log scale to create 
a scatter-plot. 
FIG. 19 shows the effect of sample volume on protein 
fractionation. Panel a shows the protein recovery from frac-
tionation experiments performed using different amount of 
serum on the same chip type. The amount of protein recov- 
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ered is very low when only 1 and 5 µA of serum are used. 
Protein recovery reaches a plateau when 10 µA of serum are 
used. The incubation of 20 and 50 ld of serum did not result in 
a higher protein recovery. Panel b shows that the amount of 
protein in the washing samples increases with the increase of 
the serum used for fractionation. 
FIG. 20 shows the effect of surface area on protein frac-
tionation, specifically, the protein recovery from 12 indepen-
dent experiments performed with increasing amount of serum 
samples (5, 10, 20 and 50 µl) on different nanoporous surface 
areas (diameters equal to 3.25, 6.5 and 10 mm; same chip 
type) using the same settings (temperature, time, washings). 
FIG. 21 is a table showing a summary of physical proper-
ties of all the nanoporous chips manufactured and character-
ized in this study. 
FIG. 22 shows the effect of pore volume on protein frac-
tionation. Panel a shows the characteristic pore volume of 22 
chips, which was calculated considering the diameter of the 
surface used for the fractionation, the thickness of the chip 
and its porosity. Panel b shows the amount of protein recov-
ered from each of the chips using the same experimental 
settings. Panel c shows that protein recovery and pore volume 
are directly and linearly correlated. Panels d and e show the 
MALDI spectra of the recovery from crude serum, non 
porous silica and chip X11, in the peptide and protein range 
respectively. 
FIG. 23 shows the two-way hierarchical clustering analysis 
of fractionation of serum on different chips. In Panel a, unsu-
pervised two-way hierarchical clustering analysis (two-di-
mensional complete linkage) was performed based on the 
intensity of detected proteomic features after fractionation on 
the different chips. The intensity of the red or green color 
indicates the relative protein concentration, that is, higher 
than or lower than the average value, respectively (black is the 
average value). Each row represents an individual peak signal 
and each column represents an individual sample (Chip). 
Each set of nanochips is clearly individualized. The dark and 
light blue rectangles represent large and small pores, respec-
tively. The green and red rectangles represent the hydropho-
bic and TMB agent nanochips, respectively. Panel b shows 
supervised hierarchical clustering and specific recovery pat-
tern for each set of nanochips as indicated in the figure 
(smaller vs. larger pores, hydrophobic vs. hydrophilic, TMB 
vs. PPG). 
FIG. 24 is the physical characterization of the MSC. Panel 
a shows 1D XRD patterns and TEM images of plan-view 
(inserted) for mesoporous silica thin film prepared using 
CTAB, F127, and L121+50% PPG templates. Panel b shows 
pore size distribution from BJH adsorption for mesoporous 
silica thin films prepared using CTAB, F127, and L121+50% 
PPG templates. The corresponding adsorption/desorption 
isotherms are inserted. 
FIG. 25 shows the principle of MSC fractionation and 
LMW enrichment. In Panel a, after sample spotting on the 
surface, LMW proteins and peptides are trapped into the 
pores while the larger species remained outside the pores and 
are removed during the washing steps. The enriched fractions 
are then eluted and analyzed by MALDI. Panels b-g show the 
detection of the molecular weight standards by MALDI-TOF 
in the peptide (800 to 10000 Da) and in the protein range 
(3000 to 100000 Da). For the separated mixes of peptides (16 
markers from 900 to 8500 Da) and proteins (16 markers from 
3400 to 66500 Da), the profiles present a high level of detec-
tion for each species. 
FIG. 26 shows the molecular cut-off and size-dependent 
enrichment of the MSC. Panel a shows a magnified view of 
the MALDI spectra demonstrating the characteristic molecu- 
8 
lar cut-off of each MSCs correlating to the pore size. Panel b 
shows the MALDI profiles of the HMW region for the stan-
dards solution before (Std) and after fractionation on 11.7 and 
9.0 nm pores MSC. Panel c shows two-way hierarchical clus- 
5 tering of the peptide mix features among the different chips. 
The intensity of the red or yellow color indicates the relative 
peptide concentration. Larger pores enhanced the harvesting 
of bigger peptides (from 3600 to 8500 Da), while the small 
peptides (from 900 to 3500 Da) were preferentially recovered 
io from the chips with smaller pores. Panel d shows the MALDI 
profiles of the LMW region for the standards solution before 
(Std) and after fractionation on 11.7 and 9.0 nm pores MSC. 
FIG. 27 shows the effects of physico -chemical modifica-
tions on the LMW enrichment. Panel a shows the intensity bar 
15 graph of specific peptides recovery on 3D-Cubic and 
3D-Hexagonal F127 MSC. The different structural modifica-
tions present a selective enrichment. Panel b shows the MS 
profiles of selectively captured peptides on the chemically 
modified chips. Positively and negatively charged MSC spe- 
20 cifically enrich negative and positive peptides respectively. 
FIG. 28 shows the molecular cut-off of the modified MSC. 
Panel a shows pore structural transformation. The molecular 
cut-off for the 3.9 mu mesoporous thin films fabricated using 
F127 is similar (20575 Da) for both 3D cubic and 3D honey- 
25 comb hexagonal structures. Panel b shows the chemical func-
tionalization. The molecular cut-off for the 6.2 mu mesopo-
rous thin films fabricated using L121 is similar for both 
cationic (NH+) and anionic (SH-) surfaces. 
FIG. 29 shows the purity of MPS thin films. XPS core level 
30 spectra was used to analyze the relative amounts of C, Si, and 
O on the surface of a mesoporous silica thin film prepared 
from Plutonic L121. The tabulated atomic concentration of 
each element is shown in the lower right. 
FIG. 30 shows the efficacy of serum fractionation using the 
35 mesoporous silica thin film chips. MALDI MS profiles are 
shown in both the low mass range (900 to 10,000 Da) and the 
high mass range (3,000 to 70,000 Da) before (a, b) and after 
(c, d) fractionation using the mesoporous silica thin films. The 
molecular recovery is significantly reduced when using blank 
4o non-porous silica surfaces for fractionation (e, f). 
FIG. 31 shows a statistic study of reproducibility of on-
chip fractionation. Panel a shows the coefficient of variation 
(CV) distribution of MS intensities for detected peaks. The 
average CV is indicated in the figure. Panel b the linear 
45 regression analysis of average intensities of detected MS peak 
in each replicate compared to replicate 1. The equation and 
the coefficient of determination (R 2) are presented 
FIG. 32 shows the physical characterizations of MPS thin 
films. XRD patterns (a, c, e), TEM (inset a, c, e), and N 2 
5o adsorption/desorption analysis (pore size distribution in b, d, 
f, isotherms in the insets of b, d, f), of the structural transfor-
mation of mesoporous thin films prepared using Pluronic 
F127 at different concentrations in the precursor solution: 
4.0x10-3 M (a, b), 6.0x10-3 M (c, d) and 8.0x10 -2  M (e, f). 
55 FIG. 33 shows the molecular cut-off for F127 chips. The 
molecular cut-off of recovered proteins is shown for the MPS 
thin films prepared by Pluronic F 127 with different nanoscale 
morphologies: 3D cubic (a), 3D honeycomb hexagonal (b) 
and 2D hexagonal (c). 
60 	 FIG. 34 shows the effect of pore structural transformation 
on LMWP recovery from F127 chips. The MALDI profiles 
for the 3D cubic (a), 3D honeycomb hexagonal (b) and 2D 
hexagonal (c) nanoscale morphologies, respectively. The 
coefficient of variation (CV) distributions of MS peak inten- 
65 sities for each of the MALDI profiles are also shown (d, e, f). 
The average CV and the number of detected peaks are indi-
cated in each histogram. 
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FIG. 35 shows XRD spectra and STEM images (inset) of 
mesoporous silica thin films prepared using a. P123 at P123/ 
TEOS=5.9x10-3 , b. F127 atF127/TEOS -1.13><l0-2 , c. L64 
atL64/TEOS=2.14x10-2, d. L121 atL121/TEOS=1.09x10 -z 
with PPG at a molar ratio of 1:0.5. The STEM images are 5 
obtained normal to the thin film surface. 
FIG. 36 shows pore size distribution of mesoporous silica 
thin films prepared with different triblock copolymer tem-
plates and the corresponding adsorption/desorption isotherm 
(inset): a. P123; b. L121 and L121 with swelling agent (PPG) 10 
at molar ratios of 0.5 and 1.0. 
FIG. 37 shows contact angle goniometry for MPS thin 
films. a. A representative image of contact angle measure-
ments for the mesoporous silica chips prepared using L121; b. 15 
A chart of contact angles for all mesoporous silica thin film 
chips developed. 
FIG. 38 shows the effect of pore size on LMWP recovery. 
a. Mass spectra of the proteins and peptides collected from 
samples fractionated using chips prepared with L64, F127, 20 
L121+50% PPG and L121+100%PPG (top to bottom), b. MS 
profiles of the samples fractionated using chips prepared with 
P123, c. The supervised hierarchical clustering analysis of 
peak intensities for samples fractionated using chips prepared 
withF127, L64, L121+50%PPGandL121+100%PPG. Red 25 
indicates peak intensities higher than the median value, green 
is for peak intensities lower than the median value, and black 
represents peak intensities equal to the median value. Each 
row represents an individual mass peak (MALDI MS peak) 
and each column represents a mesoporous thin film chip 30 
produced using a specific triblock copolymer. 
FIG. 39 shows the molar ratio of starting materials used to 
fabricate the mesoporous silica thin films and their final 
physical properties, as characterized by ellipsometry and N z 35 
adsorption/desorption isotherms, for the four different block 
copolymers, P123, F127, L64, L121 and L121 with two dif-
ferent molar ratio of swelling agent. 
FIG. 40 shows the XPS spectra of mesoporous silica chips 
with APTES modification. Panel (a) present a comparison of 40 
C content in XPS on the mesoporous silica chips before and 
afterAPTES modification. Panel (b) presents a comparison of 
N content in XPS on the mesoporous silica chips modified 
with one-spot synthesis (black curve), modified with post-
grafting without pre-treatment (red curve) and modified with 45 
post-grafting with oxygen plasma treatment (blue curve). 
FIG. 41 shows the effects of chips functionalization on the 
LMW enrichment. MALDI-MS profiles of selectively cap-
tured peptides on the chemically modified chips. Positively 
and negatively charged mesoporous thin films specifically 50 
enrich negative and positive peptides respectively. 
FIG. 42 shows the charge specific recovery for the chips 
with different surface functions. Bar graph of the MS inten-
sity of detection of selectively captured peptides on the func-
tionalized chips. According to their iso-electric point, the 55 
peptides are positively or negatively charged at pH 7.0. Panel 
(a) depicts positive peptides (1 des-Argl-Bradykinin, 
2 Bradykinin, 3-Substance P-amide, 4 Neurotensin, 
5 ACTH(1-17), 6 ACTH(7-38)) are specifically enriched 
on the negatively charged surfaces. Panel (b) depicts negative 60 
peptides (7 Glul-Fibrinopeptide B, 8 a-Endorphin, 
9 ACTH(18-39), 10 Insulin, 11 EGF, 12—Insulin-like 
GFII) are specifically enriched on the positively charged sur-
faces. 
FIG. 43 is composed of a series of XPS survey scans 65 
providing the elemental composition of the functionalized 
pore surfaces (a, Zr4+, c. Ti4+ and e. Ga 3+), and XPS high  
10 
resolution scans of the core elements providing information 
about the immobilized metal ions (b, Zr 4+, d. Ti4+ and f. 
Ga3+) 
FIG. 44 depicts the small angle XRD patterns (0.2°-6°) for 
the MPS thin film of Example 6. 
FIG. 45 depicts TEM images of the MPS thin film of 
Example 6, functionalized by (a) Ga 3+, (b) Ti4+ and (c) Zr4+ 
and their EDX spectra: (d) Ga 3+, (e) Ti4+ and (f) Zr4+ 
FIG. 46 depicts the MALDI TOE spectra of fractionated 
peptides processed by the Zr4+ immobilized chip of Example 
6, from (a) raw a-casein, (b) trypsinized a-casein, (c) 
trypsinized a-casein treated with phosphatase, and (d) raw 
a-casein treated with phosphatase. 
FIG. 47 depicts the MALDI TOE spectrum MS spectra of 
the fractionated samples on the Zr 4+ immobilized chip of 
Example 6, from (a) raw phosvitin in human serum, (b) 
trypsinized phosvitin in human serum, (c) trypsinized phos-
vitin, treated with phosphatase, inhuman serum (d) raw phos-
vitin treated with phosphatase inhuman serum and (e) human 
serum. 
FIG. 48 depicts the unsupervised hierarchical clustering 
analysis for the ability of the MPS chips immobilized with 
different metal ions for LMW phosphopeptide recovery 
(Cluster A: Zr4+, Cluster B: Ga3+, and Cluster C: Ti 4+) . Red 
indicates peak intensity higher than the median value, green 
indicates peak intensity lower than the median value, and 
black represents peak intensity equal to the median values. 
Each row represents an individual MALDI MS mass peak and 
each column represents a type of fractionated sample, with 
unprocessed phosphopeptide sample as a negative control. 
The samples are divided by (a) Raw a-Casein, (b) 
Trypsinized a-Casein, (c) Trypsinized a-Casein treated with 
phosphatase, (d) Raw a-Casein treated with phosphatase. 
DETAILED DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
Unless otherwise specified, the words "a" or "an" as used 
herein mean "one or more". 
In general terms, a novel size-exclusion strategy is pre-
sented based on Mesoporous Silica Chips (MSC) for the 
efficient removal of the high molecular weight proteins and 
for the specific isolation and enrichment of low molecular 
weight species present in complex biological mixtures. In 
combination with mass spectrometry profiling, significant 
improvement and optimization of the specific harvesting effi-
cacy of the MSC is presented. 
A method is provided wherein components in a sample can 
be fractionated or separated. In an exemplary method 
embodying principles of the present invention, a substrate is 
provided which includes a mesoporous material having two 
or more domains, and the presence of the two or more 
domains allows for the separation and/or fractionation of the 
components in the sample into the two or more domains by 
contacting the mesoporous material with the sample. The 
number of domains present on a single mesoporous material 
is limited only by the physical size of the material, and can 
number in the thousands. 
Mesoporous materials can be used for fractionation, stabi-
lization, and storage of low-molecular weight biomolecules 
that are present in very low concentration in complex biologi-
cal fluids. The mesoporous materials can be designed to pos-
sess desired physical and chemical features such as porosity, 
pore size, pore structure, and surface properties to selectively 
fractionate and enrich biomolecules. The fractionated bio-
molecules can be stabilized once captured in the pores of 
mesoporous materials, and the stabilization can be indepen- 
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dent of storage temperature. Hence, mesoporous materials 	 It is possible that one domain on the mesoporous material 
can be used to fractionate, stabilize, store, and transport frac- 	 adsorbs the first component. The domains on the mesoporous 
tionated biomolecules for on-site or off-site application. 	 material can have a modified surface that is electrically 
Exemplary embodiments of mesostructured materials 	 charged or modified with organic functional groups or inor- 
include mesoporous materials such as nanoporous silicon and 5 ganic metal ions, or both, and the modified surface of one 
nanoporous oxide materials such as nanoporous silica. Exem- 	 domain can be different from the modified surface of another 
plary mesoporous materials have pore diameters of between 	 group. 
about 2 nm and about 50 nun. Nanoporous materials typically 	 The components which are separated into the domains on 
encompass a range from about 1 nm up to about 1000 mu. See 	 the mesoporous material may be analyzed by methods which 
J. Roquerol et al. "Recommendations for the characterization io include, but are not limited to, mass spectrometry, gel elec- 
of porous solids (Technical Report)" Pure &Appl. Chem., 66 	 trophoresis, chromatography, bioassay, or a combination 
(1994) 1739-1758. 	 thereof, and the mass spectrometry can be MALDI-TOF mass 
Mesoporous materials can be fabricated by a surfactant- 	 spectrometry, LC/MS mass spectrometry, ESI-MS mass 
templated sol-gel process, for example. The obtained mate- 	 spectrometry, tandem mass-spectrometry, and/or SELDI 
rials can be films, wafers, particles, powders, microchips, etc. 15 mass spectrometry. 
The mesoporous materials can be differentiated by their 	 Mesoporous materials such as mesoporous films can be 
physicochemical properties such as pore size, pore structure, 	 produced by the evaporation-induced-self-assembly (EISA) 
porosity, and functional groups. For example, the mesopo- 	 procedure, and as a result can have a tunable and pre-deter- 
rous materials can be multi-domain chips. The chips can be 	 minable pore size, texture, and structure. The EISA synthesis 
used for fractionation and enrichment of biomolecules in a 20 route is adaptive and makes it possible to immobilize or 
selective molecular range or in multiple selective molecular 	 embed organic functional groups or inorganic metal ions and 
ranges. 	 to modify surface physicochemical properties, such as pore 
The physicochemical properties of the mesoporous mate- 	 size, volume, texture, and structure. The pore morphology 
rials can function to stabilize the captured biomolecules, and 	 can be pre-determined to be, for example, cubic, hexagonal, 
prevent denaturation or degradation of captured biomol-  25 honeycomb-like, tubular, circular, and/or oblong. The pore 
ecules. Biomolecules fractionated from multiple selective 	 size can also be the same or different among the various 
ranges can be stabilized in a single multi-domain chip. 	 domains, and can be, in one example, between 1 nun to 30 nun, 
The fractionation operation can be parallel or sequential. 	 and in another example, between 2 nm and 15 nun, more 
The physicochemical properties of the mesoporous materials 	 preferably between 2 nun and 12 nun. Pore volume can also be 
can be correlated with their fractionation properties and iden-  30 pre-determined, can be the same or different among the vari- 
tified by molecular cut-offs. The fractionated biomolecules 	 ous domains, and can be in one example, between 4 and 15 nl. 
can be stabilized once captured in the mesoporous materials. 	 Examples of the mesoporous materials include mesopo- 
The mesoporous material may function as a molecular cut- 	 rous chips. Exemplary mesoporous chips can generate a mul- 
off. 	 tiplicity of peaks for cross-correlation and multivariate profile 
The fractionated biomolecules can be stabilized once cap-  35 analysis centigrams. The correlation between physical and 
tured in the mesoporous materials. The captured biomol- 	 chemical features (porosity, pore size and structure and sur- 
ecules can be stabilized when the physicochemical properties 	 face properties) of the chips and the biomolecular fractions 
of the mesoporous materials inhibit the activity of lytic 	 can be established. The capture of desired biomolecular frac- 
enzymes. The captured biomolecules can be stabilized when 	 tions is effective at extremely low concentration ranges of the 
the physical dimensions of the nanofeatures of mesoporous 40 target biomolecules even in the presence of the overwhelming 
materials are smaller, comparable, or bigger than lytic 	 background of highly abundant proteins in serum, plasma, 
enzymes. The captured biomolecules can be stabilized due to 	 and whole blood. The chips allow for selective capture and 
chemical properties of the mesoporous materials. The meso- 	 enrichment of samples as small as 10 ld with excellent rapid- 
porous materials can be used as storage containers of frac- 	 ity, require no sample pre-processing, and are highly repro- 
tionated biomolecules for long periods of time. The mesopo-  45 ducible. 
rous materials can be used to transport biological samples to 	 The chips are not limited to mesoporous silica films. Other 
remote sites and for off-site application. 	 surfactant-templated mesoporous materials may also be 
The mesoporous materials can be utilized to sequester 	 applied. Mesoporous silica chips are described here as an 
desired low-molecular weight biomolecules present in very 	 exemplary embodiment. 
low concentration in samples of complex biological fluids. 50 	 Mesoporous silica films can be fabricated on a substrate 
The sample can be any biological fluid derived from a living 	 such as silicon or a glass wafer by coating, such as spin- 
body including, but not limited to, blood serum, blood 	 coating, dip-coating, printing, or deposition. The coating 
plasma, blood, urine, seminal fluid, seminal plasma, pleural 	 solution may be a sol-gel solution of an orthosilicate com- 
fluid, ascites, nipple aspirate, feces, saliva, cerebrospinal 	 pound, such as a silica source, solvent, water, acid or base, and 
fluid, etc. The body from which the biological sample is taken 55 surfactant polymer at a certain ratio. The surfactant-template 
may have a physiological condition that can be identified by 	 can be removed by chemicals or by heating after coating. The 
methods embodying principles of the present invention. 	 obtained mesoporous films may possess different physico- 
The components in the sample can be numerous, and can 	 chemical properties such as pore size, pore structure, poros- 
include, but are not limited to, proteins, antigens, antibodies, 	 ity, functional groups, etc. The mesoporous film may be dif- 
proteins, protein fragments, RNA, DNA, etc. The compo-  60 ferentiated by morphology or structure. The morphologic or 
nents may have differing molecular weights. For example, the 	 structural variation can be induced during the synthetic pro- 
molecular weight of a first component can be lower than the 	 cedure. 
molecular weight of a second component. 	 The obtained mesoporous silica films can be treated in 
Exemplary methods of the present invention can include 	 oxygen plasma. In one embodiment, the mesoporous silica 
the step of extracting the first component from the mesopo-  65 films are treated in oxygen plasma prior to conjugating 
rous material and washing the mesoporous material subse- 	 organic functional groups. This helps to ensure the hydrophi- 
quent to contacting the mesoporous material with the sample. 	 licity of the silica film. Furthermore, it is believed that the 
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silanol (Si OH) groups on the surface of the mesoporous 
silica films act as a convenient point for further organic func-
tionalization of the film, though the high temperature during 
calcinations process may cause portions of the surface sil-
anols groups to be extensively dehydrated, resulting in a 
substrate incompatible with potentially conjugating orga-
nosilane groups. However, the oxygen plasma treatment 
restores the defective points (Si H on the mesoporous silica 
and generates a high density of Si OH groups. 
The mesoporous silica films can be differentiated by adapt-
ing different swelling agents in the synthesis procedure. The 
mesoporous silica films can also be differentiated by their 
chemical modification or biological conjugation with differ-
ent functional groups or molecules, for example to permit the 
selective enrichment of low-abundance and low molecular 
weight biomarkers, such as those found in human serum. For 
example, organic functional groups with various charges and 
polarities, including but not limited to phosphate, amine, 
thiol, carboxy acid, sulfate acid and epoxy moieties, may be 
conjugated within the nanoporous matrix. Alternatively, the 
mesoporous film may be conjugated with chemical functional 
groups on the pore surface. For example, silage compounds 
with the functional groups aminopropyltriethoxysilane 
(APTES) and mercaptopropyltriethoxysilane may be used for 
amine attachment. Likewise, the surface of mesoporous silica 
chips can be coated by hydrophobic molecules such as, in one 
example, hexamethyldisilazane. 
In addition to the organic functional groups discussed 
above, the present invention contemplates the use of inor-
ganic metal ions to functionalize the surface of the mesopo-
rous silica. For example, metal ions such as gallium, zirco-
nium and titanium (e.g. Ga 3+, Ti4' and Zr4') may be 
immobilized on mesoporous silica chips as a means to 
improve the detection limit of very low concentration pep-
tides, particularly low molecular weight phosphoproteins. 
The chemical and physical properties of the composite meso-
porous thin films may then be characterized by X-ray diffrac-
tion, transmission electronic microscopy, X-ray photonic 
spectroscopy, energy dispersive X-ray spectroscopy and 
ellipsometry. 
Post-functionalization of the mesoporous silica films 
effectively reduces the detectable concentration threshold by 
removing dominant high molecular weight proteins. Further-
more, capture selectivity may be increased, enhancing the 
ability of the inventive mesoporous films to resolve the dif-
ference between the modified protein and its unmodified pre-
cursor, where the mass to charge ratio is nearly identical and 
may obscure the desired phosphopeptide peak. The function-
alized mesoporous silica films of the instant invention thus 
demonstrate tunable selectivity coupled to a platform capable 
of much higher throughput. 
The mesoporous silica films can be patterned or masked to 
work as biomolecular fractionation chips. The chips can be 
used for fractionation and enrichment of the selective 
molecular range species using an on-chip fractionation strat-
egy. The chips with different physicochemical properties can 
be integrated in a single chip to form a combinatorial multi-
domain chip. The domains can be distinguished by their 
physicochemical properties, and may be from the same film 
or different films. By using micro/nanofabrication tech-
niques, thousands of domains can be fabricated on a single 
chip. 
The combinatorial multi-domain chips can be masked or 
patterned to define sample area, and/or isolate samples. Mask 
materials can be photolithography compatible polymers/pho-
toresists, molded PDMS films, silicone rubbers, and so forth. 
The mask can be made to match a multichannel pipette sys- 
tern for automation. The masks can be removable. The chips 
can be made so they are able to be directly inserted into to a 
measurement system such as MS. 
The physicochemical properties can be characterized by 
5 many methods. For example, the thickness and porosity of 
obtained films can be determined by a spectroscopic ellip-
sometry. The surface area and pore size distribution of the 
mesoporous films can be measured using N 2 adsorption-des-
orption isotherm. The morphology and structure can be mea- 
10 sured by Transmission Electron Micrographs of the sections 
or SEM. Small angle X-ray scattering spectra (SAXS) can be 
used to determine the structural symmetry. The physico-
chemical properties of the chips or domains can be correlated 
with their fractionation properties and identified the molecu- 
15 lar cut-offs. 
While the invention has been described in detail with ref-
erence to exemplary embodiments thereof, it will be apparent 
to one skilled in the art that various changes can be made, and 
equivalents employed, without departing from the scope of 
20 the invention. The foregoing description of the preferred 
embodiments of the invention has been presented for pur-
poses of illustration and description. It is not intended to be 
exhaustive or to limit the invention to the precise form dis-
closed, and modifications and variations are possible in light 
25 of the above teachings or may be acquired from practice of the 
invention. The embodiments were chosen and described in 
order to explain the principles of the invention and its practi-
cal application to enable one skilled in the art to utilize the 
invention in various embodiments as are suited to the particu- 
30 lar use contemplated. It is intended that the scope of the 
invention be defined by the claims appended hereto, and their 
equivalents. The entirety of each of the aforementioned docu-
ments is incorporated by reference herein. 
35 	 EXAMPLES 
The present invention will be more concretely explained 
below with reference to the following non-limiting 
Examples. 
40 
Example 1 
Example 1.1 
45 	 Fabrication of Mesoporous Proteomic Chips 
The coating solution was a mixture of a tetra-ethyl-ortho- 
silicate (TEOS) as silica source, solvent, water, acid, and 
surfactant polymer at designed ratio. The stock solution was 
50 prepared first: 10 g of TEOS (Sigma Aldrich) was first added 
to a glass bottle followed by 8.5 g of absolute ethanol (Sigma 
Aldrich). Then, 1 g deionized (DI) water was added, and 
finally, 0.04 g of 0.07M HCl (Sigma Aldrich) solution was 
added. This mixture was stirred and heated to 60° C. for 90 
55 minute. Then, the solution was cooled down, and aged at least 
two days before use. For Pluronic F38, F88, F108 and F127 
tri-block copolymer (BASF) which are solid at room tem- 
perature, 4 g of the triblock copolymer was first dissolved in 
8 g ethanol and 4 g water. Next the 8.7 g stock solution and the 
60 1.2 g 1M HCl solution were added. The mixture was then 
vibrated on a Vortex mixer for 1 min, and processed by ultra- 
sound for 5 min. The obtained clear solution was aged for 1 
day before spin-coating. The film was made by spin-coating: 
1.5 ml of coating solution was dispersed onto a 4" silicon 
65 wafer (Silicon Quest International, Inc, CA) and spun at 600 
rpm for 5 s, and then the spinning speed was increased to 3000 
rpm for 30 s. The coated wafer was placed in an oven, heated 
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to 80° C., aged for 15 h. The temperature was then raised to 	 to derive any diagnostic or otherwise medically significant 
425° C. at a rate of 5° C./min. The wafer was kept at 425° C. 	 information. The fundamental, clinically enabling advantage 
for 4 h, and slowly cooled down to room temperature. The 	 of the present approach is that whole blood can be drawn and 
SU-8 photoresist mask was patterned on the mesoporous 	 directly placed onto the MSC, resulting in a pattern of stored 
silica chips (hereinafter, "MSCs") using standard photoli-  5 information that is reproducible and stable in time, regardless 
thography to form a hydrophobic ring to confine the sample of a broad range of temperature and environmental variables. 
within the non-covered area. Fabrication of Polydimethylsi- 
loxane (PDMS) masked MSC was started by molding the 	 Example 1.3 
PDMS film, and then bonded to MSCs (See FIG. 1). 
10 	 Protein Fractionation Experimental Procedure 
Example 1.2 
The MSC surface was wetted using isopropanol, washed 
Protein Fractionation, Stabilization and Storage 	 with sterile H 20, and air dried. For each experiment, a sample 
amount of either plain human serum, or a solution containing 
The MSCs for protein fractionation and enrichment of the 15 different dilutions of recombinant peptides and proteins, was 
LMW species were employed using a fast three step on-chip 	 pipetted into the circular area defined by the different masks. 
fractionation strategy, and showed the correlation between 	 Unless otherwise specified, for all the experiments shown in 
pore size, the molecular weight of the trapped species, and the 	 the paper 10 ld of sample were used for each analysis. The 
enrichment of the LMW standards. The use of MS profiling to 	 samples were incubated for 30 minutes in a wet chamber 
correlate a disease with the specific changes in the circulating 20 (100% humidity) to prevent sample evaporation. In order to 
proteins is a promising tool to improve diagnosis, to allow the 	 identify the best working condition experiments were per- 
design of personalized therapies and to follow their efficacy in 	 formed at either 4° C., 25° C. (RT), or 37° C. RT was selected 
real time and with low invasiveness. However, several publi- 	 as the optimal temperature and used for all the experiments 
cations reported that pre-analytical sample management may 	 showed in the paper. MSCs were washed 5 times with 15 µL 
lead to significant alterations of the proteomic profiles and the 25 of sterile, deionized water, allowing the droplets to rest on the 
generation of possible artifacts. Reproducibility and reliabil- 	 surfaces for 0.5 minute for each wash. The chips were dried 
ity of the approach are crucial for any clinical applications. 	 after the washing steps, and stored for up to 3 weeks. Peptides 
The consistency of the on-chip fractionation assay was 	 and proteins were eluted by using 10 ld of a 1:1 mixture of 
assessed at different working temperatures (FIG. 3), and by 	 acetonitrile and 0. 1 % trifluoroacetic acid (TEA) (v/v) (Sigma) 
reproducing the same experiment in 6 replicates with 6 ali-  30 and pipetting the solution on the chip for approximately 1 
quots of the same human serum sample. After fractionation, 	 minute. Aliquots of 1 µL of the mix of serum extracts and 
the spectra of the replicates showed a highly reproducible MS 	 matrix solutionwere deposited on a MALDI sampleplate and 
signal (See FIG. 6a). The reproducibility of the procedure 	 allowed to dry prior to mass spectrometric analysis. Protein 
was statistically evaluated for the relative intensities of the 	 content in samples was measured using a microBCA assay 
detected peaks in the range of 900 to 20000 Da. The regres-  35 (Pierce, Rockford, Ill.) and read with the absorbance at 562 
sion curves and equations comparing the peak intensities 	 nun on a UV/Vis Spectrophotometer (Spectra Max M2, 
recovered from the replicates in crude and fractionated serum 	 Molecular Devices). Absorbance values were converted into 
are illustrated in FIGS. 10f and 1 O respectively. The general 	 protein amounts using the formula calculated through a stan- 
variability of the peak signals measured by the average CV 	 dardization curve. For the microBCA assay, 3, 5, 8, 10, and 12 
was estimated at 12.7% for crude serum and 14.2% after 40 µL of the sample for washes 1-5 respectively and 3 µL of the 
fractionation. The statistical evaluation of the data obtained 	 elution sample were diluted in water to make 500 µL. This 
indicated marginal variations due to the internal variability of 	 diluted protein was mixed with 500 µL, of the microBCA 
the MALDI instrument and revealed that the on-chip pretreat- 	 buffer and incubated for 1 hour at 60° C. The samples were 
ment did not induce any alteration of MS protein profiles. To 	 allowed to cool to room temperature and then read on the 
address the issue of protein stability in the nanopores MSCs 45 spectrophotometer. 
were incubated with human serum, dried the chips after the 
washing steps, and stored them for 3 weeks. The stability of 
	
Example 1.4 
peptides and proteins was confirmed using samples eluted 
from chips after 3 weeks storage at room temperature (see 	 Mass Spectrometry 
FIG. 3e). Compared with a freshly fractionated sample of the 50 
same serum, the results demonstrated similar peptide patterns 	 A matrix solution of 5 mg/ml a-cyano-4-hydroxycinnamic 
as shown above. It is hypothesized that LMW species trapped 	 acid (oLCHCA, Sigma) in a 1:1 mixture of acetonitrile and 
inside the nanopores were preserved from degradation 	 0.1% TFA(v/v) and a saturated matrix solution of trans-3,5- 
through the exclusion of the proteases from the nanopores, or 	 dimethoxy-4-hydroxycinnamic acid (SA, Sigma) in 2:1 mix- 
by the steric inhibition of their proteolytic activity in the 55 ture of acetonitrile and 0.1 % TEA was used for Low Molecu- 
confined space of the nanopores. The ability to impede further 	 lar Weight (LMW) and High Molecular Weight (HMW) 
degradation of the proteins and peptides once they are cap- 	 peptides and proteins, respectively. Each sample was mixed 
tured mesopores is a crucial property for the translation into 	 with the appropriate matrix in a 1:3 ratio, and spotted in 
the laboratory clinical practice. It enables the establishment 	 duplicate onto the MALDI plate. Mass spectra were acquired 
of simple sample acquisition and storage protocols that 60 on a Voyager-DETM-STR MALDI-TOF (Applied Biosys- 
address the problem of "artifacts" that has plagued prior 	 tems, Framingham, Mass.) mass spectrometer in liner posi- 
approaches to proteomics and peptidomics. With prior meth- 	 tive-ion mode, using a 337 nm nitrogen laser. Samples were 
odologies, differences in blood sample acquisition, time 	 evaluated at two m/z ranges. For the m/z range of 800-10,000 
elapsed before contact of the serum onto the capture surfaces, 	 Da, settings were optimized at acceleration voltage 20 KV, 
environmental and storage temperatures all resulted in the 65 grid voltage 19 KV, guide wire voltage 1 KV, delay time 180 
degradation-induced appearance of peaks that confounded 	 ns, and low-mass gate 800. For the m/z range of 3,000-100, 
the analyses and rendered meaningless the use of the profiles 	 000 Da the instrument was optimized at acceleration voltage 
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25 KV, grid voltage of 23.25 KV, guide wire voltage 6.25 KV, 
delay time of 500 ns and low mass gate 3,000. Each spectrum 
was the average of 300 laser shots. The spectra were cali-
brated externally using the ProteoMass standards of peptides 
and proteins (Sigma) in each mass range. 
Example 1.5 
Data Processing and Statistics 
The raw spectra were processed with the Voyager Data 
Explorer software version 4.0 (Applied Biosystems) and the 
data were exported to SpecAlign software for pretreatment. 
All spectra were aligned using the PAFFT correlation method 
and intensity was normalized to total ion current (TIC). The 
peak detection was performed with a height ratio of 2 with 
0.3% of the mass window and the baseline was corrected and 
the negative values were removed prior to analysis. 
Hierarchical clustering was performed using Cluster soft-
ware and visualized with Treeview software. MALDI MS 
Data (M/z peak intensities) were log-transformed, normal-
ized and median centered. Pearson correlation was used to 
calculate the distance between the samples, and complete 
linkage clustering was performed. For supervised hierarchi-
cal clustering, an independent Student t-test was used for 
comparison between groups (n=2 groups) for each detected 
MS peak. A P value of 0.02 or lower was considered signifi-
cant to select differentially harvested peptides and proteins 
among the different mesoporous proteomic chips (Large 
pores vs. Small pores, Hydrophobic vs. Hydrophilic, TMB 
vs. PPG swelling agents). This statistical method was used to 
analyze and produce the data presented in FIGS. 10 and 23. 
Example 2 
Example 2.1 
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Example 2.2 
Characterization 
5 	 The thickness and porosity of calcinated films were deter- 
mined by a variable angle spectroscopic ellipsometer (J. A. 
Woollam Co. M-2000DI). Ellipsometric values, A andV were 
measured from wavelength range 3 00- 1000 run at three inci-
dence angles, 55°, 60°, 65° respectively, and fitted using 
10 Effective Medium Approximation (EMA) model with 
WVASE32 software. X-ray diffraction (XRD) patterns were 
obtained on Philips X'Pert-MPD system with Cu Ka ray (45 
W, 40 mA). 0-20 scanning were recorded from all spin- 
15 coated films at 1 s/0.001' step over the angle range from 0.2° 
to 6°. Transmission electron microscopy (TEM) was used in 
requiring micrographs of the plane view of mesoporous silica 
thin films with FEI Technai (FEI Co.) at high tension of 200 
W. The surface area and pore size distribution of the meso- 
20 porous films was measured using N2 adsorption-desorption 
isotherm on a QuantachromeAutosorb-3B Surface Analyzer. 
The sample was prepared by scraping from 6-10 mesoporous 
silica chips. The sample was degassed at 3000° C. for over 12 
hours, and the N2 adsorption-desorption isotherm was mea- 
25 sured at 77 K over relative P/P o pressures range 0.015-0.995. 
The Brunauer-Emmett-Teller (BET) surface areas were 
determined over a relative pressure range of 0.05 to 0.3. 
Nanopore size distributions were calculated from the adsorp-
tion branch of the isotherms using Barrett-Joiner-Halenda 
30 (BJH) model. Contact angles of film surface were measured 
by a goniometer with captive bubble contact angle measure-
ment. 
Example 2.3 
35 
Experimental Procedure 
Fabrication of Nanoporous Proteomic Chips 	 The molecular weight standards were combined, dis- 
pensed in equal amounts, dried by vacuum centrifugation, 
The coating solution was prepared by starting with the 40 and stored at —20° C. 10 µl of the standards solution was 
hydrolyzed silicate precursor solution. Firstly, 14 ml of tetra- 	 spotted onto the mesoporous surface of the MSC. The 
ethylortho silicate (TEOS) was added into the mixture of 17 	 samples were incubated for 30 minutes in a wet chamber 
ml of ethanol, 6.5 ml of deionized water and 2 ml of 2M HCl 	 (100% humidity) to prevent sample evaporation. The chip 
under strong stirring. The silica sol-gels were ready for use 	 surface was washed 5 times with 15 µL of sterile, deionized 
after being heated at 75' C. for 2 hours. The polymer template 45 water. Proteins were eluted from the pores by using 10 ld of a 
solutions were prepared by the addition of the calculated 	 1:1 mixture of acetonitrile and 0.1% trifluoroacetic acid 
amount of triblock polymer (BASF: L31, L35, L64, 1.5 g of 	 (TEA) (v/v). 
L121, P123, F38, F88, F108, 1.8 g of F127) or 1 g of CTAB 
in 10 ml of ethanol under room temperature. After dropping 	 Example 2.4 
10 ml of silicate precursor into the polymer solution, the 50 
mixture was kept stirring for another 2 hours (30 minutes for 	 Fractionation Procedure 
CTAB). For the preparation of mesoporous silica films with 
large pore size, a swelling agent, Polypropyleneglycol (PPG) 	 Twenty-six peptides and proteins were selected with broad 
was added in the ethanol solution of polymer before mixing 	 range of molecular weights (900-66 500 Da), pI (pI 4.0-10.2), 
with silicate. 1 ml of the coating solution was deposited on a 55 and structure. Identity and purity of each peptide and protein 
4" silicon wafer (Silicon Quest International, Inc., CA) fol- 	 was verified by MS and combined, dried by vacuum centrifu- 
lowed by spin-coating at a speed of 2500 rpm (1000 rpm for 	 gation, and stored at —20° C. The molecular weight standards 
using CTAB). The coated wafers were placed in an oven and 	 solution was prepared in 135 ld of sterile, deionized water. 
aged for 15 hours at 80° C. Then the temperature was raised 
	
The chip surfaces were wetted using isopropanol, washed 
to 425' C. at a rate of I' C./min and kept at 425' C. for 5 hours 60 with sterile H2O and air-dried. Human serum was dispensed 
to completely remove the organic components before gently 	 with a micropipette onto the surface of the wafer into the 
cooling down to room temperature. Oxygen plasma treatment 	 circular area defined by the masks. Unless otherwise speci- 
was carried out in a Plasma Asher (March Plasma System) 	 fied,10 µA of sample was used for each analysis. The samples 
with a 02 flow rate at 80 sccm and a power of 300 W for 10 	 were incubated for 30 minutes in a wet chamber (100% 
minutes. Coating of hexamethyldisilazane (HMDS) was per-  65 humidity) to prevent sample evaporation. The MSCs were 
formed in a HMDS vapor prime oven (YES) at 150° C. for 5 	 washed 5 times with 154 of sterile, deionized water. Elution 
min. 	 was performed using 10 ld of a 1:1 mixture of acetonitrile and 
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0.1 % trifluoroacetic acid (TEA) (v/v) (Sigma). Proteins were 
eluted from the pores by using 10 µL of a 1:1 mixture of CAN 
and 0.1% TEA (v/v). 
Example 2.5 
5 
Mass Spectrometry 
A matrix solution of 5 mg/ml a-cyano-4-hydroxycinnamic 
acid (oLCHCA, Sigma) in a 1:1 mixture of acetonitrile and 
0.1% TFA(v/v) and a saturated matrix solution of trans-3,5- io 
dimethoxy-4-hydroxycinnamic acid (SA, Sigma) in 2:1 mix-
ture of acetonitrile and 0.1% TEA was used for LMW and 
HMW peptides and proteins, respectively. Each sample was 
mixed with the appropriate matrix in a 1:3 ratio, and spotted 
in duplicate onto the MALDI plate. Mass spectra were 15 
acquired on a Voyager-DETM-STR MALDI-TOF (Applied 
Biosystems, Framingham, Mass.) mass spectrometer in liner 
positive-ion mode, using a 337 nm nitrogen laser. Samples 
were evaluated at two m/z ranges. For the m/z range of 800-
10,000 Da, the settings were optimized at acceleration volt-
age 20 KV, grid voltage 19 KV, guide wire voltage 1 KV, 20 
delay time 180 ns, and low-mass gate 800. For the m/z range 
of 3,000-100,000 Da the instrument was optimized at accel-
eration voltage 25 KV, grid voltage of 23.25 KV, guide wire 
voltage 6.25 KV, delay time of 500 ns and low mass gate 
3,000. Each spectrum was the average of 300 laser shots. The 25 
spectra were calibrated externally using the ProteoMass stan-
dards of peptides and proteins (Sigma) in each mass range. 
Example 2.6 
Data Processing and Statistics 	 30 
The raw spectra were processed with the Voyager Data 
Explorer software version 4.0 (Applied Biosystems) and the 
data were exported to SpecAlign (Wong, J. W., Cagney, G., 
Cartwright, H. M., SpecAlign processing and alignment of 35 
mass spectra datasets. Bioinformatics 2005, 21, 2088-2090, 
and Wong, J. W., Durante, C., Cartwright, H. M., Application 
of fast Fourier transform cross-correlation for the alignment 
of large chromatographic and spectral datasets. Anal Chem 
2005, 77, 5655-5661) software for pretreatment normalized 40 
to total ion current intensity. The baseline was corrected and 
the negative values were removed prior to analysis. Hierar-
chical clustering was performed using Cluster software and 
visualized with Treeview software. The MALDI Data (M/z 
peak intensities) were log-transformed, normalized and 45 
median centered. Pearson correlation was used to calculate 
the distance between the samples, and complete linkage clus-
tering was performed (Eisen, M. B., Spellman, P. T., Brown, 
P. 0., Botstein, D., Cluster analysis and display of genome-
wide expression patterns. Proc Natl Acad Sci USA 1998, 95, 
50 14863-14868). For supervised hierarchical clustering, an 
independent Student t-test was used for comparison between 
groups (n=2 groups) for each detected MS peak. A P value of 
0.02 or lower was considered significant to select differen-
tially harvested peptides and proteins among the different 
55 
nanoporous proteomic chips (Large pores vs. Small pores, 
Hydrophobic vs. Hydrophilic, TMB vs. PPG swelling 
agents). 
Example 3 
60 
Example 3.1 
Fabrication and Characterization of Mesoporous 
Proteomic Chips 
65 
The coating solution for the mesoporous silica thin films 
with various pore size and morphological properties were 
20 
produced using different surfactant polymers as synthetic 
templates under acidic conditions. The pH of precursor solu-
tions was controlled at 1.5 to prevent the precipitation of 
nanoporous silicate and balance the procedure between the 
silicate hydrolysis and condensation of hydrolyzed silicate to 
polymer micelle. In FIG. 7 are illustrated the schematics of 
the chemical composition of the coating solution during the 
production of the mesoporous silica films (FIG. 7a-d) and the 
assembly of the final chips (FIG. 7e f). Manufacturing proto-
cols were optimized in order to obtain the mesoporous silica 
chips with smooth, crack-free surfaces across 4" silicon 
wafers with a porous films' thickness from 700 to 900 mu. 
Porosity was related to the ratio between copolymer and 
TEOS, while the thickness was determined by many factors, 
including the concentration of surfactant, the spin-coating 
speed, and the aging time of the coating solution. The pore 
alignment was induced by strain during the spin-coating pro-
cess (Rice, R et al., "Structural comparison of hexagonally 
ordered mesoporous thin films developed by dip- and spin-
coating using X-ray reflectometry and other quantitative 
X-ray techniques", Journals of Materials Chemistry 2005, 
15, 4032-4040]. 
Mesoporous silica thin films were first examined by X-ray 
diffraction (XRD) to display the periodicity and the organi-
zation of pore's nanostructure (FIG. 24a). The XRD pattern 
obtained with the CTAB silica thin film shows a peak for 
(200) reflection at 2.20° of 20 with d 200 3.16 nm representing 
a periodic 3D cubic structure of silica nano-composite 
formed along the surface of the substrate. The XRD pattern of 
the F127 chip exhibits an ordered nanoporous texture as 
indicated by the highly intense (100) reflection peak at 
20-0.99° (d,,,-9.01 nm). The lower intensity peaked at 
(110) with d,,,-6.30 nm and (200) with d2oo=4.75 nm speci-
fies the formation of a 3D honeycomb nanostructure. The 
XRD pattern for the L121 chip displays no peak in the small 
angle range illustrating the formation of disordered pores. 
Transmission electron microscopy (TEM) of each polymer 
template performed on the plane view confirmed the XRD 
results on the ordering and the nanostructure of the different 
chips. To determine the shape and the pore size distribution, 
N2 adsorption-desorption isotherms measurements were per-
formed (FIG. 24b). According to the standard of the Interna-
tional Union of Pure and Applied Chemistry (Sing, K. S. W., 
Everett, D. H., Haul, R. A. W., Moscou, L., et al., Reporting 
Physiosorption Data for Gas Solid Systems with Special Ref-
erence to the Determination of Surface-Area and Porosity 
(Recommendations 1984). Pure and Applied Chemistry 
1985, 57, 603-619), the isotherms can be classified as a Type 
II displaying a Hl hysteresis loop for CTAB chips, and as 
Type-IV with H2 hysteresis loops for F127 and L121 chips 
indicating the formation of ink-bottle shape nanopores. For 
this type of isotherm, adsorption branch of the isotherm can 
be used to calculate the pore size distribution using BJH 
method. All the BJH pore size distributions exhibits sharp 
peaks, which imply that both periodic and non-ordered 
nanophases created on the chips present uniform pore sizes. 
Different chemical modifications were also studied. Oxy-
gen plasma treatment was applied to ensure the hydrophilic-
ity of the surface of the silica films, while HMDS coating was 
applied to make the surface hydrophobic. The hydrophilicity 
of the films was evaluated through contact angle measure-
ment. The 02 plasma treated films shows <15' contact angle, 
while the HMDS coated film showed >65' contact angle. 
Example 3.2 
Enrichment of the LMW Proteome 
High-throughput mass spectrometry is a gold standard for 
protein expression profiling and for disease-related biomar- 
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ker discovery. However, the current MS technologies are not 	 polymer templates from ionic and non-ionic triblock copoly- 
able to profile the entire proteome and particularly the LMW 	 mers with different volume ratio of hydrophilic/hydrophobic 
species because of the interfering signals generated by the 	 composition as shown in FIG. 24. Because of its highest 
highly abundant HMW proteins (Tirumalai, R. S., Chan, K. 	 hydrophobic/hydrophilic ratio among pluronic surfactants, 
C., Prieto, D. A., Issaq, H. 7., et al., Characterization of the low 5 L121 is capable of forming the mesoporous silica with the 
molecular weight human serum proteome. Mol Cell Proteom- 	 largest porosity (-65%) and pore size (6.2 mu). F127 tem- 
ics 2003, 2, 1096-1103). To address this limitation, a fraction- 	 plate presents an intermediate pore size (3.9 mu) while the 
ation method was developed using the MSC to efficiently and 	 smallest pore size (2.0 mu) can be obtained using the ionic 
specifically enrich the LMW proteome from complex bio- 	 surfactant CTAB. In addition, by applying a different ratio of 
logical samples. The principle of this fast on-chip fraction-  10 swelling agent such as Poly Propylene Glycol (PPG) to the 
ation strategy is shown in FIG. 25a: 1 The sample is spotted 
	
L121 pluronic surfactant, the pore size has been further 
on the chip surface and LMW molecules are trapped into the 	 enlarged to obtain MSC with 7.4 mu, 9.0 nm and 11.7 mu. To 
pores during the incubation step; 2-The larger protein spe- 	 evaluate the molecular cut-off and the enrichment properties 
cies remain outside the pores and are removed during the 	 of the different pore sizes, the solution of peptide and protein 
washing steps; 3 The enriched small molecules are then 15 standards were fractionated on the set of MSC ranging from 
eluted from the pores and further analyzed by MS. In order to 	 2.0 to 11.7 mu. The removal of the large proteins is size 
evaluate the fractionation and enrichment efficacy of this 	 dependant as illustrated by the gradual decrease of the 
on-chip strategy, and to characterize how the physico-chemi- 	 molecular cut-off observed for the different chips (FIG. 26a). 
cal properties of the chips correlate with their harvesting 	 The silica surface with 9.0 mn pores did not completely 
properties, 26 standard peptides and proteins were selected 20 exclude albumin, accordingly to its three-dimensional struc- 
with a broad range of molecular weights (900-66,500 Da) and 	 ture which exhibits an average size of 8 by 3 mu. This analysis 
isoelectric points (pI 4.0-10.2), and combined to represent the 	 demonstrates the size exclusion principle of the mesoporous 
diversity and complexity of biological samples (See FIGS. 4 	 chip fractionation, and reveals the limit of this depletion 
and 5). FIGS. 25b and 25c show the high detection signals of 	 approach observed with the 11.7 nm pores which provides a 
the standards when separated into two different solutions for 25 similar MS pattern to the non-fractionated sample (FIG. 26b). 
the peptide range (16 markers from 900 to 8500 Da) and the 	 In addition to the size-dependant depletion of high molecular 
protein range (16 markers from 3400 to 66500 Da). When 	 weight (HMW) proteins, the on-chip fractionation of the stan- 
combined in a unique solution, the detection signal in the 	 dards solution displays a differential and selective enrichment 
peptide range dramatically decreased while the larger pro- 	 of LMW species associated with the pore sizes. The two-way 
teins remained well detected (FIGS. 25d and 25e). This MS 30 hierarchical clustering presented in FIG. 26c shows the LMW 
detection signal suppression in the LMW is due to the pres- 	 standards enrichment pattern obtained with the different 
ence of large amount of well ionized HMW molecules such as 	 MSC. Even if all the peptides are below the molecular cut-off 
Albumin and other large proteins. The suppression effect 	 of the chips, there is a positive correlation between the pore 
observed with the combined solution of molecular markers 	 sizes and the molecular weight of the trapped species. The 
mimics the results obtained with MS analysis of complex 35 MSC with large pores, up to 9 mu, preferentially harvest 
body fluids such as serum and plasma. The results presented 
	
bigger peptides, while smaller peptides are recovered more 
in FIGS. 25f and 25g demonstrate the ability to eliminate the 	 efficiently by the chips with smaller pores. The chips with 
big proteins and to increase significantly the detection of the 	 11.7 nm pores present no significant improvement in the 
LMW peptides and proteins. 	 LMW region detection (FIG. 26d). This result indicates the 
The capacity of MS approaches to investigate low abun-  40 size limit of the MSC for an efficient enrichment strategy. 
dant proteins in biological samples composed of highly com- 
plex proteomes such as serum body fluids is a major issue for 	 Example 3.4 
the detection of potential biomarkers. (Hanash, S. M., Pitteri, 
S. 7., Faca, V. M., Mining the plasma proteome for cancer 	 Identification of the Selective Fractionation Patterns 
biomarkers. Nature 2008, 452, 571-579; Kulasingam, V., 45 	 Due to MSC's Nanofeatures 
Diamandis, E. P., Strategies for discovering novel cancer 
biomarkers through utilization of emerging technologies. 	 In the analysis of the fractionation and enrichment of 
Nat. Clin. Pract. Oncol., 2008, 5 588-599; Diamandis, E. P., 	 LMW species from human serum, the chips were subdivided 
Mass spectrometry as a diagnostic and a cancer biomarker 	 in 3 categories according to: 1) pore size; 2) wet ability; 3) 
discovery tool: opportunities and potential limitations. Mol. 50 pore geometry and surface morphology (Table 1). Unsuper- 
Cell. Proteomics 2004, 3, 367-378.) To assess the limit of 	 vised two-way hierarchical clustering was performed (two- 
detection of this technology, human serum sample was spiked 
	 dimensional complete linkage) to analyze the overall MALDI 
with a known peptide (Neurotensin, 1673 Da) at different 	 profiles of the different MSCs. (FIG. 10A). Depending on 
concentration levels before MSC fractionation and MALDI 
	
their harvesting characteristics, selective nanopore size and 
analysis. The results presented in FIG. 43 demonstrated the 55 specific recovery patterns, each of the MSCs consistently 
ability of the method to identify the spiked neurotensin in a 	 identified unique proteomic signatures, as shown in the super- 
concentration as low as 2 ng/mL. 	 vised hierarchical clustering (FIG. 10 B-D). The combinato- 
rial MSCs device was designed and prototyped to perform 
Example 3.3 
	
high throughput fractionation on multiple and distinctive 
60 mesoporous selection domains. Using the combinatorial 
Tunable MSC Surfaces for Selective LMW 	 multi-chip strategy and combining the MS profiles obtained 
Enrichment 	 from just six different MSCs, a three fold increase in the 
number of detected peptides and proteins in the LMW range 
In order to assess the size-dependant depletion of high 	 with respect to plain unprocessed serum was obtained (FIG. 
molecular weight (HMW) proteins, 6 proteomic chips were 65 10 E-I). These results showed that the different nanofeatures 
developed with pore sizes ranged from 2.0 mn to 11.7 mu. A 
	 (structure, size and chemistry of the pores) on the MSCs 
variety of pore sizes was first obtained by using different 	 conveyed different functionalities and served as analytical 
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"first order processors" of this technology. According to this 
strategy, a multitude of chips can be used simultaneously to 
increase the amount of information recovered from the 
serum. 
5 
24 
Example 3.6 
The Effect of Pore Morphology on Proteome 
Recovery 
Example 3.5 
Sample Stability and Reproducibility of the 
Harvesting Procedure 
Reproducibility and reliability are crucial factors for any 
assay to be used in the clinical setting. Several publications 
reported that pre-analytical sample management might lead 
to significant alterations of the proteomic profiles and the 
generation of artifacts [29, 30]. The consistency of the on-
chip fractionation assay was assessed, reproducing the same 
experiment in 6 replicates. After fractionation, the spectra of 
the replicates showed highly reproducible MS signals and 
consistent recovery. To evaluate protein stability, the MSCs 
were incubated with human serum, dried after washing, and 
stored for 3 weeks. The protein/peptide patterns obtained 
were comparable with those of freshly fractionated serum 
(FIG. 3 E), as confirmed by the results of the statistical analy-
sis shown. The variability of the peak signals measured by the 
average Coefficient of Variation (CV) was estimated at 12.7% 
for crude serum and at 14.2% for the fractionated samples. 
The marginal variations could be due to the internal variabil-
ity of the MALDI instrument and suggested that the on-chip 
pretreatment and storage did not induce any significant alter-
ation of the MS protein profiles. In analogy with previously 
postulated mechanisms, it is hypothesized that the LMW 
species trapped inside the nanopores were preserved from 
degradation through the exclusion of proteases from the nan-
opores, or by steric inhibition of their proteolytic activity in 
the confined space of the nanopores (Luchini, A, Geho, D. H., 
Bishop, B., Tran, D. et al., Smart hydrogel particles: biomar-
ker harvesting: one-step affinity purification, size exclusion, 
and protection against degradation. Nano Lett. 2008, 8, 350-
361; Vaithesswaran, S., Thirumalai, D., Interactions between 
amino acid side chains in cylindrical hydrophobic nanopores 
with applications to peptide stability, Proc. Natl. Acad. Sci. 
2008, 105, 17636-17641.) 
The establishment of a simple sample acquisition and stor-
age protocol, and the ability to impede further degradation of 
the proteins and peptides once they are captured, are essential 
for translation into the laboratory clinical practice (Banks, R. 
E., Stanley A. 7., Cairns, D.A., Barrett, J. H. et al., Influences 
of blood sample processing on low-molecular weight pro-
teome identified by surface-enhanced laser desorption/ion-
ization mass spectrometry, Clin. Chem. 2005, 51, 1637-1649; 
Ransohoff, D. F., Lessons from controversy: ovarian cancer 
screening and serum proteomics. J. Natl. Cancer Inst. 2005, 
97, 315-319.). With prior methodologies, deceptive results 
confounded the analysis and rendered meaningless the use of 
the profiles to derive any significant diagnostic or clinical 
information (Diamandis, E. P., Mass spectrometry as a diag-
nostic and a cancer biomarker discovery tool: opportunities 
and potential limitations, Mol. Cell. Proteomics 2004, 3, 367-
378; Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. 
J. et al., Use of proteomic patterns in serum to identify ovarian 
cancer. Lancet 2002, 359, 572-577; Ransohoff 2005). On the 
contrary, after processing on the MSCs, the resulting protein 
patterns were reproducible and consistent even after a long 
term on-chip storage and regardless of the range of tempera-
tures and environmental variables. 
Besides the size dependant fractionation, the selective 
parsing of the enriched peptides into different subclasses 
according to their physicochemical properties would improve 
the efficiency of the on-chip strategy. Given the tunability of 
10 silica thin film material, the effect of pore morphology on 
proteome recovery was investigated. Starting with Pluronic 
F127 block copolymer, the periodic nanostructure of the 
pores can be transformed from a cubic to a hexagonal hon-
eycomb like 3-dimensional (3D) architecture by tuning the 
15 molar ratio of silicate to polymer template. The average pore 
size remaining identical, the 2 different F 127 MSC present a 
similar molecular cut-off (See FIG. 12a), which demonstrates 
the same size exclusion property. However, their harvesting 
capacity offers differential peptide enrichment. As shown in 
20 FIG. 27a, there is a significant increase of the capture of 
ACTH and Insulin peptides on the hexagonal surface while 
Substance P and a-Endorphin peptides are specifically recov-
ered from the cubic MSC. 
Another important factor to improve the enrichment capac- 
25 ity of the MSC is to resolve the complexity of biological 
samples in different sub-proteomes according to their chemi-
cal properties. MSCs conjugated with chemical functional 
groups on the pore surface have been developed. The chips 
have been modified using silane compounds with the func- 
30 tional groups aminopropyltriethoxysilane (APTES) for 
amine attachment, and mercaptopropyltriethoxysilane 
(MPTMS) for sulfhydryl attachment to provide cationic and 
anionic surfaces respectively. MS analysis of the proteomic 
standards solution fractionated on 6 run MSC chips conju- 
35 gated with the chemical functional groups is presented in 
FIG. 27b. According to their Isoelectric Point (IP), the posi-
tively charged and negatively charged LMW standards are 
captured on the anionic and the cationic chips respectively. 
HMW proteins remain excluded from the chips indepen- 
40 dently from their charge (See FIG. 28b). For example, Albu-
min has a net negative charge and remains excluded from the 
cationic chip. These results and the identical molecular cut-
off offer displayed by the chips demonstrate the dual proper-
ties of the functionalized MSC (see FIG. 28): 1-the size 
45 dependant depletion of HMW proteins by the porous surface; 
2 the specific enrichment of differentially charged LMW 
peptides. 
Example 4 
50 
Example 4.1 
Fabrication of Mesoporous Proteomic Chips with 
Different Physicochemical Property 
55 
Mesoporous silica chips (MSCs) with different pore size 
were made by spin-coating a silicate sol-gel solution on a 
silicon wafer. The coating solution was a mixture of a tetra-
ethyl-ortho silicate (TEOS) as silica source, solvent, water, 
6o acid, and surfactant polymer at designed ratio. The stock 
solution was prepared at first: 10 g of TEOS (Sigma Aldrich) 
was first added in a glass bottle, then, 8.5 g of absolute ethanol 
(Sigma Aldrich) was added, next, 1 g deionized (DI) water 
was added, and finally, 0.04 g of 0.07M HCl (Sigma Aldrich) 
65 solution was added. This mixture was stirred and heated to 
60'C. for 90 minute. Then, the solution was cooled down, and 
aged at least two days before use. The coating solution was 
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made by adding 8.7 g stock, 8 g ethanol, 0.6 g water, 1.0 g 	 recorded over the angle range 0° to 5°. Contact angles of film 
0.07M HCl, and 1.8 g of triblock copolymer (Pluronic L31, 	 surface were measured by a goniometer with captive bubble 
L35, L64, or L121 triblock copolymer (BASF)) in this order. 	 contact angle measurement. 
The mixture was vibrated on a Vortex mixer for 1 min and 
	
The porosity of the selected MSCs ranged from 40% to 
ultrasound for 5 min. The obtained clear solution was aged for 5 70%, the pore volume in a circular area of 6 mm in diameter 
1 day before spin-coating. The film was made by spin-coat- 	 from 6.0 to 12.3 nl as obtained from ellipsometry measure- 
ing: 1 . 5 ml of coating solution was dispersed onto a 4" silicon 	 ment. The Nz adsorption -desorption isotherms of six selected 
wafer, and spun at 600 rpm for 5 s, and then the spinning 	 MSCs are shown in FIG. 8a. The isotherms can be classified 
speed was increased to 3000 rpm for 30 s. The coated wafer 	 as Type-IV curve with H2 hysteresis loops, according to the 
was placed in an oven, heated to 80° C., aged for 15 h. The 10 standard of the International Union of Pure and Applied 
temperature was then raised to 425 ° C. at a rate of 5° C./min. 	 Chemistry. This type ofhysteresis indicated ink-bottle shaped 
The wafer was kept at 425' C. for 4 h, and slowly cooled down 	 pores, and non-ordered worm-like pore arrangement . For this 
to room temperature. Oxygen plasma treatment of the films 	 type of isotherm, adsorption branch of the isotherm can be 
was carried out in a Plasma Asher (March Plasma System). 	 used to calculate the pore size distribution . The pore size 
Coating of Hexamethyldisilazane (HMDS) was performed in 15 distribution curves of six MSCs with worm-like inter-con- 
a HMDS vapor prime oven (YES) at 150° C. for 5 min. 	 nected pore structure (for easy pore accessibility) were 
derived from adsorption isotherms using Barrett-Joyner-Hal- 
Example 4.2 	 enda (BJH) method and are shown in FIG. 8a (average sizes 
ranging from 2.7 mu to 8.9 mu). The reflection Small Angle 
Mask Machining and Prototype Device Integration 	 20 X-ray Scattering (SAXS) curves of the films are shown in 
FIG. 8b. The curves were recorded 2 cm off the center of the 
Silicone rubber masks were machined using 1.6 mm thick 
	
4" wafer, with the beam incidence along the direction of 
silicone rubber sheets (transparent, 40 DURO hardness, with 	 radius. The SAXS curve showed a peak around 0.5°-0.7° 
adhesive layer from 3M) obtained from McMaster-Carr. The 	 (corresponding to d-space around 13 - 17 nm) suggesting a 
sheets were cleaned and cut to 100 mmx100 mm squares. A 25 periodic spatial variation of the electron density in the film, 
home-machined 8x8 hole punch matching 64 channel pipette 	 and some degree of alignment of the pores. The pore align- 
was used to make the silicone rubber mask . The MSCs were 	 ment was induced by strain during the spin-coating process. 
diced into 9x9 mm squares. 64 squares from different MSCs 	 By comparing the SAXS curves at 
~
-90° and 
~
-0° (see FIG. 
were attached on a 100 mm glass wafer , and then the silicone 	 12), a differential pore alignment along and perpendicular to 
rubber mask was aligned and assembled on top of the MSC 30 the radius of the wafer was discovered. This was further 
squares. FIG . 1 illustrates the schematics of the chemical 	 confirmed by AFM measurement of the film surface by show- 
composition of the coating solution during the production of 
	
ing different dimensions of the features along and perpen- 
the mesoporous films (FIG. 7a-d) and the assembly of the 	 dicular to the radius (FIG. 12c) and by TEM imaging (see 
final chips (FIG. 7e-h). Manufacturing protocols were opti- 	 FIG. 13 ). Different chemical modifications were also studied. 
mized in order to obtain MSCs with smooth, crack-free sur-  35 Oxygen plasma treatment was applied to ensure the hydro- 
faces across 4" silicon wafers (FIG. 7i -j, k-o). Three different 	 philicity, while HMDS coating was applied to make the sur- 
masks with defined rounded areas of different diameters were 	 face hydrophobic. The hydrophilicity of the films was evalu- 
designed to optimize proteomic sampling. 	 ated through contact angle measurement (see FIG. 14). Films 
treated with O z plasma showed <15' contact angle, while 
Example 4.3 	 40 HMDS coated films showed >65' contact angle. 
Characterization 	 Example 4.4 
The thickness and porosity of obtained films were deter- 	 Protein Fractionation 
mined by a M200-DI variable angle spectroscopic ellipsom-  45 
eter (J. A. Woollam Co. M-2000DI). Ellipsometric values, A 	 The MSCs were employed for protein fractionation and 
and V  were measured from wavelengthrange 300-1000 mu at 
	
enrichment of the LMW species using a fast three step on- 
three incidence angles, 55°, 60°, 65°, respectively, and fitted 	 chip fractionation strategy, as shown in FIG. 3a. The effect of 
using the Effective Medium Approximation (EMA) model 	 temperature (See FIG. 16), incubation time (See FIGS. 17 and 
with WVASE32 software . The surface area and pore size of 50 18 ), sample volume (See FIG. 19 ), surface area (See FIG. 20), 
the mesoporous films were measured using N 2 adsorption- 	 and pore volume (See FIG. 22) on protein recovery was 
desorption isotherm on a Quantachrome Autosorb-313 Sur- 	 studied, and the most stable, effective and reproducible pro- 
face Analyzer. All the samples for N 2 adsorption-desorption 	 tocol for protein fractionation was established. 
experiments were prepared by scraping 10 pieces of 4" spin- 	 More specifically, in order to identify the best working 
coated thin silica films. The sample was degassed at 300° C. 55 condition, and understand the effect of temperature on protein 
for over 12 hours, and the N 2 adsorption -desorption isotherm 	 recovery, fractionation experiments were performed at 4° C., 
was measured at —196° C. over relative P/P o pressures range 	 25° C. and 37° C. The results are shown FIG. 16 and clearly 
0.015-0.995. The Brunauer-Emmett-Teller (BET) surface 	 indicate that recovery was very low at 4° C. A tentative 
areas were determined over a relative pressure range of 0.05 	 explanations is that the mechanisms of diffusion into the 
to 0.3 . Nanopore size distributions were calculated from the 6o nanopores were slowed down at that temperature and so the 
adsorption branch of the isotherms using BJH model. 	 molecular interactions between the proteins and the silica 
Ultrathin section TEM samples were prepared as described in 	 surface. Conversely, proteinrecovery at 25° C. and37° C. was 
Supplemental Materials. Transmission Electron Micrographs 	 not significantly different . 25° C. was chosen as the optimal 
of the sections were obtained in a 200 kV FEITM TECNAITM 	 temperature and all subsequent experiments were performed 
G2 F20 X-TWIN TEM. Small angle X-ray scattering spectra 65 at room temperature (RT). This decision was also justified by 
(SAXS) were obtained on a Rigaku Smartlab horizontal 	 the fact that degradation processes such as proteolytic or 
sample mount XRD system with Cu Ka ray. 0-20 scans were 	 enzymatic digestion might take place at a higher pace at 37° 
US 8,685,755 B2 
27 
	
28 
C. This decision was also justified by the fact that degradation 	 removal of the mo st abundant HMW proteins (Albumin, Apo- 
processes such as proteolytic or enzymatic digestion might 	 lipoprotein Al and Hemoglobin) is shown in FIG. 9d by 
take place at a higher degree at 37° C. 	 comparing their signal intensities in crude serum and after 
The influence of incubation time on protein recovery was 	 fractionation. 
also studied. By running the experiment at RT with a fixed 5 	 The physico -chemical properties of the chips correlated 
volumes of serum, it was determined that protein recovery 	 with their harvesting properties was characterized and the 
reached a plateau after 30 minutes of incubation (See FIG. 	 molecular cut-offs of each MSCs was identified. 26 peptides 
17a). Further incubation time did not increase the amount of 	 and proteins (See FIG. 22 and FIG. 5) were selected with a 
protein recovered while it might have increased the chances to 	 broad range of molecular weights (900-66,500 Da), isoelec- 
have protein degradation on the chips. 	 10 tric points (pI 4.0-10.2), and structures and used them to 
Interestingly, also the amount of protein sticking to the 	 standardize the chips, the sample preparation, the MS analy- 
surface of the chip and removed during the washing steps was 	 sis and the data processing. Each peptide and protein was 
higher when the temperature was higher and the incubation 	 verified by MS for its identity and purity (see FIG. 5). In order 
time longer and the serum sample larger (See FIGS. 17-20). 	 to assess size exclusion during the fractionation, 5 MSCs with 
The effect of the amount of serum used on protein recovery 15 pore sizes ranging from 2.7 nm to 8.9 nm were selected (FIG. 
was also studied. By analyzing the data summarized in FIG. 	 8 and FIG. 11). FIG. 24a shows the high detection signals of 
19, it was concluded that, regardless of the volume of serum 	 the standards when separated into two different solutions for 
(1, 5, 10, 20, 50 µl) spotted onto the nanoporous silica chips, 	 the peptide range (16 markers from 900 to 8500 Da) and the 
the amount of recovered protein was nearly the same, with the 	 protein range (16 markers from 3400 to 66500 Da). When 
only statistically significant exceptions of the I and 5 ld 20 combined in a unique solution, the detection signal in the 
experimental points which resulted in a reduced protein 	 peptide range dramatically decreased while the larger pro- 
recovery. Protein recovery reached a plateau when 10 ld of 	 teins remained well detected (FIG. 24b). The signal suppres- 
serum were used. The incubation of 20 and 50 ld of serum did 	 sion in the LMW was due to the presence of large amount of 
not result in a higher protein recovery. In all conditions tested 	 well ionized HMW molecules such as Albumin and mim- 
and in accordance with our previous results, the protein 25 icked the limits of MS analysis of serum and plasma. The data 
amount in washes number 4 and 5 was lower than the amount 	 presented in FIG. 25 demonstrate the ability to exclude the 
of protein recovered in the elution steps (See FIG. 17c). 	 larger proteins and to increase significantly the detection of 
In a set of 12 independent experiments, various amounts of 	 the LMW peptides and proteins. FIG. 26 gives a magnified 
serum sample (5, 10, and 50 µl, brought to the same final 	 view of the spectra illustrating the size-dependent removal of 
volume of 50 ld by adding deionized sterile water) were 30 the larger proteins and the experimental molecular cut-off 
applied on different nanoporous surface areas (diameters 	 evaluated for each chip. FIG. 26c presents a two-way hierar- 
equal to 3.25, 6.5 and 10 mm; same chip type, see FIG. 7 j, 1, n) 	 chical clustering showing the positive correlation between 
using the same settings (temperature, time, washings). Pro- 	 pore size, the molecular weight of the trapped species and the 
tein recovery from the smallest area (3.25 mm) is signifi- 	 enrichment of the LMW standards. MSCs with larger pores 
cantly lower than that obtained from the intermediate and 35 preferentially harvested bigger peptides (from 3600 to 8500 
larger areas (See FIG. 20). Independently from the amount of 	 Da), while smaller peptides (from 900 to 3500 Da) were 
serum used, protein recovery reached a plateau on 6.5 mm 	 recovered more efficiently by the chips with smaller pores. 
diameter nanoporous surfaces when 10 ld of serum were 	 In the analysis of the fractionation and purification of 
used. When a larger fractionating area was used (10 mm 	 LMW species from human serum, the chips were subdivided 
diameter), protein recovery progressively increased with the 40 in 3 categories according to the properties of the material: 
amount of serum spotted on the surface. 	 1 pore size; 2 hydrophobicity; 3 pore geometry and sur- 
These results could be explained by the fact that more than 	 face morphology. Unsupervised two-way hierarchical clus- 
the amount of serum, it was the binding capacity of the porous 	 tering (two-dimensional complete linkage) was performed to 
silica and the available volume of the pores, to be relevant for 	 analyze the overall MALDI profiles of the different nano- 
protein recovery. To better understand the mechanism under-  45 chips. FIG. 10a presents the resulting dendogram of samples 
lying protein recovery, all the chips were characterized and 	 clusters (the total hierarchical cluster is presented in FIG. 23). 
the pore volume for each one of them was calculated. The 	 According to their harvesting characteristics, selective 
complete list of the physico -chemical features of the chips is 	 enrichment and specific recovery patterns, each of the MSCs 
summarized in the table in FIG. 21. Using the same experi- 	 identified unique proteomic signatures, as shown in the super- 
mental protocol (fixed volume of serum: 10 µA; temperature: 50 vised hierarchical clustering (FIG. 10b-d; see also the hierar- 
25° C.; incubation time: 30 min; fractionating area: 6.5 mm), 	 chical clusters with the mass list in FIG. 23b). The MS pro- 
protein recovery was measured on each of the chips (FIG. 	 files of fractions obtained from the prototype device were 
22b). By correlating protein recovery and pore volume (FIG. 	 combined (FIG. 10e-h) and demonstrated that the number of 
22a), it was determined that there was a linear dependence 	 detected peptides and proteins in the LMW range was 
between the efficiency of protein recovery and the total vol-  55 increased using the combinatorial multi-chip strategy (FIG. 
ume of the nanopores (FIG. 22c). This is a further demonstra- 	 10: 3 fold increase compared to untreated serum). 
tion that the physical properties of the nanoporous silica chips 
could be tuned and tailored to achieve the desired amount of 
	
Example 4.5 
protein to be recovered. As a control, the fractionation proto- 
col was performed on non-porous silica and showed that 60 	 Protein Fractionation Experimental Procedure 
neither proteins nor peptides were captured by the nonporous 
silica surface (FIG. 22 d and e, respectively). 	 The MSC surface was wetted using isopropanol, washed 
The MS profiles of human serum before and after fraction- 	 with sterile H2O and air dried. For each experiment, a sample 
ation on the MSCs were compared (FIG. 9b). The substantial 	 amount, which consisted of either plain human serum, or a 
enrichment of LMW species is illustrated in FIG. 9c by com-  65 solution containing different dilutions of recombinant pep- 
paring the MALDI intensities of common peptides and pro- 	 tides and proteins, was pipetted into the circular area defined 
teins before and after the on-chip fractionation. The efficient 	 by the different masks. Unless otherwise specified, for all the 
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experiments shown in the paper 10 µA of sample were used 
for each analysis. The samples were incubated for 30 minutes 
in a wet chamber (100% humidity) to prevent sample evapo-
ration. In order to identify the best working condition experi-
ments were performed at either 4° C., 25° C. (RT), or 37° C. 
RT was selected as the optimal temperature and used for all 
the experiments showed in the paper. MSCs were washed 5 
times with 154 of sterile, deionized water, allowing the drop-
lets to rest on the surfaces for 0.5 minute for each wash. 
Peptides and proteins were eluted by using 10 ld of a 1:1 
mixture of acetonitrile and 0.1% trifiuoroacetic acid (TEA) 
(v/v) (Sigma) and pipetting the solution on the chip for 
approximately 1 minute. Aliquots of 1 µL of the mix of serum 
extracts and matrix solution were deposited on a MALDI 
sample plate and allowed to dry prior to mass spectrometric 
analysis. Protein content in samples was measured using a 
microBCA assay (Pierce, Rockford, Ill.) and read with the 
absorbance at 562 nm on a UV/Vis Spectrophotometer (Spec-
tra Max M2, Molecular Devices). Absorbance values were 
converted into protein amounts using the formula calculated 
through a standardization curve. For the microBCA assay, 3, 
5, 8, 10, and 12 µL of the sample for washes 1-5 respectively 
and 3 µL of the elution sample were diluted in water to make 
500 µL. This diluted protein was mixed with 500 µL of the 
microBCA buffer and incubated for 1 hour at 60° C. The 
samples were allowed to cool to room temperature and then 
read on the spectrophotometer. 
Example 4.6 
Mass Spectrometry 
A matrix solution of 5 mg/ml a-cyano-4-hydroxycinnamic 
acid (oLCHCA, Sigma) in a 1:1 mixture of acetonitrile and 
0.1% TFA(v/v) and a saturated matrix solution of trans-3,5-
dimethoxy-4-hydroxycinnamic acid (SA, Sigma) in 2:1 mix-
ture of acetonitrile and 0.1 % TEA was used for Low Molecu-
lar Weight (LMW) and High Molecular Weight (HMW) 
peptides and proteins respectively. Each sample was mixed 
with the appropriate matrix in a 1:3 ratio, and spotted in 
duplicate onto the MALDI plate. Mass spectra were acquired 
on a Voyager-DETM-STR MALDI-TOF (Applied Biosys-
tems, Framingham, Mass.) mass spectrometer in liner posi-
tive-ion mode, using a 337 nm nitrogen laser. Samples were 
evaluated at two m/z ranges. For the m/z range of 800-10,000 
Da, settings were optimized at acceleration voltage 20 KV, 
grid voltage 19 KV, guide wire voltage 1 KV, delay time 180 
ns, and low-mass gate 800. For the m/z range of 3,000-100, 
000 Da the instrument was optimized at acceleration voltage 
25 KV, grid voltage of 23.25 KV, guide wire voltage 6.25 KV, 
delay time of 500 ns and low mass gate 3,000. Each spectrum 
was the average of 300 laser shots. The spectra were cali-
brated externally using the ProteoMass standards of peptides 
and proteins (Sigma) in each mass range. 
Example 4.7 
Data Processing and Statistics 
The raw spectra were processed with the Voyager Data 
Explorer software version 4.0 (Applied Biosystems) and the 
data were exported to SpecAlign software for pretreatment. 
All spectra were aligned using the PAFFT correlation method 
and intensity was normalized to total ion current (TIC). The 
peak detection was performed with a height ratio of 2 with 
0.3% of the mass window and the baseline was corrected and 
the negative values were removed prior to analysis. 
30 
Hierarchical clustering was performed using Cluster soft-
ware and visualized with Treeview software. MALDI MS 
Data (M/z peak intensities) were log-transformed, normal-
ized and median centered. Pearson correlation was used to 
5 calculate the distance between the samples, and complete 
linkage clustering was performed. For supervised hierarchi-
cal clustering, an independent Student t-test was used for 
comparison between groups (n=2 groups) for each detected 
MS peak. A P value of 0.02 or lower was considered signifi-
cant to select differentially harvested peptides and proteins 
among the different mesoporous proteomic chips (Large 
pores vs. Small pores, Hydrophobic vs. Hydrophilic, TMB 
vs. PPG swelling agents). 
15 	 Example 5 
Methods and Materials 
20 	 Example 5.1 
Fabrication and Characterization of Mesoporous 
Silica Thin Films 
25 	 Most of the procedures used for the synthesis of mesopo- 
rous silica films are similar to the ones described by Zhao et. 
al. (Science, 1998, vol 279: 548-553). The primary objective 
of this study was to tailor MPS thin film pore morphology and 
internal structure by adjusting synthetic parameters and to 
30 explore their efficacy for the specific harvesting of LMWP 
species from human serum. A consistent proteomic profiling 
approach requires that the MPS-based serum fractionation be 
performed with a well defined high purity substrate possess-
ing good thermal stability as well as uniform nanostructure 
35 and film thickness throughout the entire mesoporous silica 
layer. The preparation of the precursor solution, involving the 
cooperative assembly of a polymer surfactant and soluble 
silicate species, play a dominant role in determining the 
molecular organization of the final product. The molar ratios 
40 of starting materials are listed in Table 1 for each block 
copolymer used. To prevent shrinkage of the MPS thin films, 
deposited film thickness did not exceed 1 µm. This was 
accomplished by maintaining the molar ratio of ethanol to 
silicate to between 12 and 14 and water to silicate at less than 
45 6. The pH of the precursor solution was kept in the range of 
1.2 to 1.5 in order to avoid the precipitation of silicate and to 
achieve equilibrium between the condensation of silicate onto 
the polymer micelles and its hydrolysis in solution. Porosity 
and pore structure were adjusted by changing the molar ratio 
50 of the polymers in the mixture. Spin coating, superior to other 
deposition techniques for achieving uniform thickness and 
porosity, was used to form the MPS thin films on a silicon 
substrate. The substrates were then cleaved to produce chips 
for quantitative proteomics analysis. Previous literature has 
55 demonstrated that mesoporous silica products can exhibit 
substantial non-uniformity as a result of inadequately con-
trolled synthesis due to the weak interaction between mol-
ecules during the self-assembly process. Other experimental 
parameters, such as aging time of the precursor solution, 
60 coating speed during solution deposition, and calcination 
temperature were studied to understand their impact on the 
final features of the mesoporous structure. To reduce experi-
mental complexity, only the amphiphilic structure of the 
block co-polymers and their concentration in the precursor 
65 solution were adjusted, with all other process parameters held 
constant, to investigate their effect on pore geometry, mor-
phology, and connectivity. 
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To characterize the pore architectures and physico-chemi-
cal properties of MPS thin films, various techniques were 
employed, including ellipsometry, 1-dimensional X-ray dif-
fraction (1D-XRD), Nz adsorption/desorption, transmission 
electron microscopy (TEM), X-ray photoelectron spectros-
copy (XPS) and surface contact angle goniometry. FIG. 29 
depicts the overall purity and the atomic silicon-to-oxygen 
ratio of the MPS thin films prepared with L121 as the struc-
ture-directing template are determined by XPS using the 
Si2p, Ol s and Cl s regions of the spectra. The very weak 
signal for the Cls region can be attributed to minimal con-
tamination (i.e. hydrocarbons) on the film surface. Both the 
Si2p and Ols regions consisted of a sharp and symmetric 
single peak at binding energies around 101.4 eV and 530.7 eV 
respectively, which strongly point to a silica framework with 
high condensation. By calculating the areas under the peaks 
for Si2p and Ol s, an atomic silicon-to-oxygen ratio of 
1:2.004 was obtained to further confirm the high purity of 
MPS thin films. Similar XPS results were acquired for MPS 
thin films synthesized using the alternative polymer tem-
plates. 
Example 5.2 
fore, fractionation reproducibility and reliability are manda-
tory for any further development of a reliable proteomic and 
peptidomic screening techniques for clinical applications. To 
assess the consistency of the on-chip fractionation strategy, 6 
5 replicates with 6 aliquots of the same human serum sample 
were screened using MPS thin films prepared by L121+PPG 
with a molar ratio of 1:0.5. The general variability of the peak 
signals is illustrated on the histogram displaying the repara-
tion of the coefficients of variation (CV) measured for each 
10 detected peak (FIG. 31a). The average CV was estimated at 
13.1%, which demonstrated a high reproducibility for the 
detected peaks over a wide mass range of 800 to 20,000 Da. 
The regression curve and equation comparing the peak inten-
sities recovered from the replicates are illustrated in FIG. 3 l 
15 and exhibit a coefficient of regression R 2-0.988. These 
results confirmed that the on-chip serum fractionation did not 
induce any significant variability in the sample and demon-
strated the reliability of the MPS chips in the pre-treatment of 
complex biological samples. The minor statistical variations 
20 are due to the internal variability of the MALDI instrument. 
Example 5.4 
Effect of Pore Structure and Distributional 
Serum Fractionation on Mesoporous Silica Thin 	 25 	 Architecture on LMWP Recovery 
Films 
The protocol for serum fractionation using MPS thin films 
is described in the experimental section. Briefly, the serum 
sample was first spotted on the MPS chip and incubated at 
room temperature for 30 minutes. This procedure trapped 
LMW molecules in the pores while the larger proteins 
remained in solution on the MPS thin film surface. After 
multiple washings with deionized water to remove the large 
proteins from the surface, the trapped LMWP was eluted 
from the pores using an acidic solution. FIGS. 30a and 30b 
show the MS spectra of a serum sample with peptides in the 
range of 900 to 10,000 Da and proteins in the range of 
(3,000-70,000 Da) respectively which have not undergone 
fractionation by the MPS thin films. These spectra illustrate 
the signal suppression in the LMW region due to the presence 
of well ionized, highly abundant, high molecular weight 
(HMW) proteins (Albumin, ApoAl). FIGS. 30c and 30d 
depict the MALDI-TOF spectra of the serum sample after 
fractionation by the MPS thin films synthesized using L121 
and swelling agent PPG at a molar ratio of 1:0.5. Enrichment 
of the LWM components is clearly evident as the majority of 
the large molecules in the serum sample haven been removed. 
As a control, the same serum sample was applied onto a 
nonporous pure silica surface to evaluate the specificity of 
MPS thin films for LMWP recovery. As can be seen in FIGS. 
30e and 30f, there was no significant harvesting of peptides or 
proteins from the nonporous silica surface observed in the 
range of interest for both the peptide and protein mass. Thus 
it can be concluded that it was the mesoporous architecture 
and not the silica surface affinity that constitutes the predomi-
nate factor in the enrichment of LMWP. 
Example 5.3 
Reproducibility of Serum Fractionation on 
Mesoporous Silica Thin Films 
Due to the relative instability of blood samples, several 
publications have reported the importance of pre-analytical 
sample management to avoid the accumulation of artifacts 
and significant alterations in the proteomic profiles. There- 
One main advantage of block copolymers with high 
molecular weight, in comparison to those of low molecular 
weight, is their ability to form a variety of structures by tuning 
30 experimental conditions during MPS thin film synthesis. The 
structural transformation of the mesoporous arrangement was 
carried out by tuning the concentration of the template poly-
mer. Increasing the concentration of the template polymer 
resulted in a reduced interfacial curvature between the phases 
35 of the water, the copolymer, and the silicate, consequently 
initiating the interrelated progression from a spherical to a 
cylindrical structure. Pluronic F127, with its high molecular 
weight, possesses this high degree of structural periodicity. In 
this study, the concentrations of all starting materials, except 
4o F127, were kept constant. FIG. 32 demonstrates the changes 
in the nanostructure of the MPS by characterization through 
XRD pattern, TEM imaging and N 2 adsorption/desorption 
analysis. When the F127 concentration in the precursor solu-
tion was kept at 4.Ox 10 -3 M, the final MPS thin film acquired 
45 a 3D cubic structure with reflection peaks at (100) and (I 10) 
and a low intensity peak at (220) as indicated by the XRD 
pattern (FIG. 32a) and further verified through TEM imaging 
(inset of FIG. 32a). Nz adsorption/desorption curves were 
generated using a Quantachrome Autosorb-3b BET Surface 
5o Analyzer (inset of FIG. 32b) and the pore size distribution 
was calculated using the Barrett-Joyner-Halenda (BJH) 
method (FIG. 32b). The adsorption/desorption isotherms 
describe a Type IV isotherm with a H2 hysteresis loop (slop-
ing adsorption branch and nearly vertical desorption branch) 
55 indicating a nanoporous structure with interconnecting chan-
nels. Inflection points appearing at 0.40 :5P/Po:50.75 in the 
figure indicated the formation of ink-bottle shape nanopores. 
Increasing the F127 concentration to 6.0x10 -3 M yields a 3D 
honeycomb like nanostructure hexagonally arranged on the 
60 substrate, as confirmed by XRD, with peaks at (200) and 
(400) (FIG. 32c), and TEM (FIG. 32c inset). The adsorption/ 
desorption isotherms, depicted with the pore size distribution 
in the inset of FIG. 32d, vary slightly from the similar adsorp-
tion-desorption Type VI isotherms described for the lower 
65 concentration F127 MPS thin films due to the increased inter-
nal pore connectivity. A further increase of the F127 concen-
tration to 8.0x10-3 M resulted in a 2D hexagonal nanostruc- 
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ture parallel to the substrate surface. The sharp peaks at (100) 
and (300) in the XRD pattern (FIG. 32e) and TEM imaging 
(FIG. 32e inset) confirm this conclusion. The adsorption/ 
desorption isotherms (FIG. 32f inset) displays a narrow hys-
teresis loop indicating significantly less inter-pore connectiv-
ity than either of the previous two MPS thin film 
morphologies. The similar pore size distributions of the 3 
different nanostructure, with average pore sizes around 3.7 
mu, illustrate that the change of pore size was minimally 
dependent on the molar ratios of the starting materials. 
After demonstrating that it was possible to fabricate MPS 
thin films with different pore morphology, the effect of the 
structural variation of the mesoporous F127 nanochips (31) 
cubic, honeycomb hexagonal and 2D hexagonal) on the spe-
cific enrichment of LMW species was investigated. As shown 
in FIG. 33, MPS thin films with similar pore size distribu-
tions, around 3.7 to 3.9 mu, and the three different nanostruc-
tures (FIG. 33a for 3D cubic, FIG. 33b for 3D honeycomb-
like hexagonal and FIG. 33c for 2D hexagonal) exhibit the 
same molecular cut-off for peptide and protein recovery from 
serum fractionation. For both 3D nanoporous morphologies, 
the increased pore connectivity and the reduced steric hin-
drance imposed on the diffusion of peptides and proteins 
resulted in higher recovery efficacy. The dramatic difference 
in the MS profiles for peptides recovery in the range of 
800-10,000 Da between 3D nanostructures and 2D hexago-
nal framework was shown in FIG. 34a, c b and e. The average 
coefficient of variation (CV) determined from the histograms, 
for 3D cubic structure (FIG. 34b) or 3D honeycomb hexago-
nal structure (FIG. 34d) is considerably lower than that of the 
2D hexagonal architecture (FIG. 34f), which shows a broader 
CV distribution. These results indicate that the serum frac-
tionation on the MPS thin film with a 3D nanotexture pos-
sesses a comparatively lower variability because of the 3D 
structures' greater pore connectivity. 
Example 5.5 
Effect of Selecting Polymer Template on LMWP 
Recovery 
Another factor that influences the interfacial curvature 
between the polymer and the other solution components 
(TEOS, water, etc.), and thus determines the nanostructure 
and the pore size, is the hydrophilic/hydrophobic volume 
ratio of the copolymer. A series of tri-block copolymers with 
different hydrophobic (PPO) to hydrophilic (PEO) volume 
ratios were selected to synthesize the MPS thin films with 
different pore sizes and morphologies and subsequently 
investigated for their LMWP harvesting efficacy. Block 
copolymer compositions with longer PPO block lengths lead 
to increased pore size. Longer PEO block lengths for a given 
PPO block length (L121 versus P123 versus F127) lead to the 
formation of more highly ordered periodic nanostructures. 
L-type (liquid phase) block copolymers (such as L64 and 
L121) with lower PEO block lengths offer increased porosity 
due to their greater deforming performance but more chaotic 
nanostructure. FIG. 35 displays XRD patterns with the Scan-
ning Transmission Electron Microscopy (STEM) imaging 
(insets) performed for MPS thin films prepared from P123, 
F127, L64 and L121+PPG (with molar ratio of 1:0.5) detail-
ing their internal nano scale organization. In the spectra for the 
MPS thin film prepared with P123 (molar ratio P123/ 
TEOS=5.9x10-3) (FIG. 35a), the appearance of an intense 
and narrow peak for the (200) reflection at 1.66° of 20 and 
d200 5.31 nm combined with a lower intensity (3 10) peak at 
20=2.99° indicate the formation of a hexagonally arranged 
periodic silica nano-composite thin film after calcination at 
425° C. The absence of the (I 10) reflection indicates that the 
(100) plane of the 2D hexagonal unit cell was parallel to the 
surface of the silicon substrate. The plane view of STEM 
5 imaging shows the continuous mesochannels on the top of the 
film and provides the direct evidence for the formation of a 2D 
hexagonal nanostructure. The MPS thin film prepared with 
F127 (FIG. 35b) (molar ratio F127/TEOS — LI3x10-2) also 
exhibits an ordered nanoporous morphology indicated by the 
io highly intense (100) reflection peak at 20-0.99 1 (d,,,-8.89 
mu). The lower intensity peaked at (I 10) with d,,, -6.27 mu 
and (200) with d200=4.80 mu points to the formation of a 3D 
honeycomb-like hexagonal nanostructure, which is con-
firmed by the STEM imaging (FIG. 35b inset). The XRD 
15 patterns and the STEM imaging (insets) for those fabricated 
by L-type block copolymers are shown in FIGS. 35c (for L64) 
and 35d (for L121 with PPG). Their low intensity and broad 
peaks in the small angle region were caused by the formation 
of unordered worm-like nanopores. 
20 	 N2 adsorption-desorption isotherms were measured to 
assess pore size distribution and total surface area of the MPS 
thin films. The BJH pore size distributions for chips prepared 
by P123 (FIG. 36a) and L121 (FIG. 36b) are provided, each 
depicting low pore size dispersion as denoted by their sharp 
25 distribution peaks, along with their adsorption/desorption 
isotherms (insets). FIG. 36a show Type IV adsorption/des-
orption isotherms with well-defined H2 hysteresis loops. The 
MPS thin films prepared using P123 and F 127 possess similar 
mean pore size (-3.7 mu) due to their identical PPO block 
30 volume, but the MPS prepared with P123 possesses a poor 
connectivity indicated by its narrow hysteresis loop. Shown 
in FIG. 36b for chips prepared with L121, the pore diameter 
distribution peaks shift towards the right from 5.82 nm to 6.79 
mu and became broader with increasing amounts of the swell- 
35 ing agent. Their adsorption/desorption isotherms were also 
Type IV but with a HI hysteresis loop attributed to cylindri-
cally shaped pores. Adding the certain amount of PPG did not 
result in any change in the loop shape, that indicates the inner 
pore connectivity is not destructed by the swelling agent used 
40 for the chips prepared with L121. Although the MPS thin 
films prepared with L64 possesses the similar adsorption/ 
desorption isotherms with L121, its shorter hydrophobic 
chain (PPO) led to nanopores with smaller pore size (-3.2 
mu). 
45 	 The hydrophilicity of chip surface was another factor to 
consider in selecting LMWP from serum. The contact angles 
of MPS thin film surfaces were tested by captive bubble 
contact angle goniometry to characterize the hydrophilicity 
of the chips' surface. All mesoporous silica chips prepared 
50 with the four different tri-block copolymers were hydrophilic 
(contact angle <30°). FIG. 37a shows the image of a water 
droplet on the surface of a chip prepared with L121. This is a 
representative image to illustrate the high hydrophilicity of 
the MPS thin film surface. The chart in FIG. 37b details the 
55 contact angles of all MPS thin film chips that have been 
developed. The MPS thin films prepared from L121 exhibited 
the highest hydrophilicity due to the formation of their cap- 
illary condensation, increasing with the addition of the swell- 
ing agent. The MPS thin film surface prepared by P123 pre- 
60 sented the lowest hydrophilicity among all the chips 
examined in this study resulting in the highest contact angle. 
The different LMW peptide and protein enrichment spec- 
tra are illustrated in FIG. 38a for the chips prepared with L64, 
F127, L121+50% PPG and L121 +100% PPG. Though it pos- 
65 sessed a similar pore size to the MPS thin film prepared from 
F 127, the relatively higher hydrophobicity, smaller pore vol- 
ume, and poor pore connectivity of the MPS thin film fabri- 
US 8,685,755 B2 
35 
	
36 
cated with polymer P123 presented limited harvesting capa- 	 facturing. Herein the oxygen plasma restored the defective 
bility, as shown in FIG. 38b. With the largest average pore size 	 points (Si H) on MPS surface and generated a high-density 
and the highest surface hydrophilicity, the mesoporous silica 	 Si OH groups. FIG. 40a shows a comparison of XPS inten- 
chip produced using L121+PPG captured peptides and pro- 	 sity of C content on the APTES modified chips before and 
teins in a wider molecular mass range. The chips with small 5 after chemical modification. The significant increase of C Is 
pore size prepared with F127 and L64 preferentially enriched 	 peak for the chips after modification, resulting from the alkyl 
the peptides in the lower mass range. To assess this size- 	 chain onAPTES, validates the efficacy of post-grafting onthe 
dependant ability of the mesoporous silica chips to capture 	 chip surface treated with oxygen plasma. FIG. 40b exhibits 
LMWP, a hierarchical clustering analysis of peptides 	 the comparison for N 1 s peak on the 3 mesoporous silica chips 
extracted from four different mesoporous silica chips with io APTES-modified under different method (black curve: N 1 s 
various pore sizes was performed (FIG. 38c). The clustering 	 on the chips after one-spot modification, red curve: N Is on 
algorithm clearly separates the samples into two major clus- 	 the chips after post-grafting without any pre-treatment, blue 
ters representing specific proteomic patterns for smallest pore 	 curve: N is on the chips after post-grafting method with 
and largest pore chips. The high intensity of smaller LMWP 	 pre-treatment by oxygen plasma.) The difference for NI s 
was obtained with the chips prepared with L64 and F127 due 15 peak around the binding energy of 397 eV clearly implies the 
to their preferred pore sizes, 3.20 nm and 3.71 nm respec- 	 efficacy of oxygen plasma in grafting the functional groups 
tively. However, the periodic pore structure and uniform 	 on the pore surface. The chip that received pre-treatment of 
small pore size provided by F127 chips demonstrate a more 	 oxygen plasma is capable of conjugating four times the amino 
homogenous enrichment pattern. The mesoporous silica 	 content than a chip without any surface treatment. Although 
chips prepared byL121 with the pore sizes enlarged using the 20 the intensity for NI s peaks are similar, the chip carried by 
swelling agent (molar ratios of 50% to 100% PPG to template 	 post-grafting with oxygen plasma pre-treatment consisted of 
polymer) offer an increased selective capture of peptides and 	 a sharper and more symmetric single peak at binding energies 
proteins with higher molecular weight. The larger pore size 	 around 397 eV, which strongly points to a loading of APTES 
presented by the L121 with 100% PPG resulted in a more 	 with high condensation on the pore surface. 
efficient recovery as illustrated by the higher intensity of the 25 	 In order to qualitatively study the electrostatic effect on 
enrichment pattern observed on the hierarchical clustering. 	 selective on-chip fractionation, 26 standard peptides and pro- 
teins were mixed with a wide range of molecular weights and 
Example 5.6 
	
isoelectric points. MS analysis of the proteomic standards 
solution fractionated on MPS chips prepared with L121 and 
Improvement of Chemical Modification on MPS 	 30 conjugated with the chemical functional groups is presented 
Thin Film and their Effect on Specific LMWP 
	
in FIG. 41. The positively charged and negatively charged 
Recovery 	 LMW peptides are captured on the anionic and the cationic 
chips respectively. HMW proteins remain excluded from the 
Another approach to improve the enrichment capacity of 	 chips independently from their charge. For example, albumin 
the MPS chips is to resolve the complexity of biological 35 has a net negative charge and remains excluded from the 
samples by separating peptides of interest according to their 	 cationic chip. The quantitative comparison of multiple MPS 
chemical properties. Herein described are MPS chips conju- 	 chips in recovery the peptides with positive net charge is 
gated with chemical functional groups that provide cationic 	 displayed in FIG. 42a. The chips with negative charge and the 
and anionic surfaces respectively. Post-grafting is a straight- 	 chip without any modification (with a minor negative charge 
forward method to add organic groups onto the surface of the 40 originally) exhibit significantly higher enrichment for those 
pores. MPS possesses many silanol (Si OH) groups on the 	 peptides than the chip modified with APTES ( NH 2). Con- 
surface that can act as convenient anchoring points for 	 versely, the positively charged MPS chips possess excep- 
organic functionalization. However, the high temperature 	 tional capability to recover those peptides with negative net 
during calcinations process may cause a portion of surface 	 charge, as demonstrated in FIG. 42b. These results and the 
silanol groups to be extensively dehydrated, resulting in a 45 identical molecular cut-off offer displayed by the chips dem- 
substrate incompatible with potentially conjugating orga- 	 onstrate the dual properties of the functionalized MSC: 
nosilane groups. Therefore, more research groups focus their 	 1 the size dependant depletion of HMW proteins by the 
attention on one-spot synthesis. This technology involves 	 porous surface; 2 the specific enrichment of differentially 
co-condensation of tetraalkoxysilanes and organotrialkoxysi- 	 charged LMW peptides. 
lanes in the presence of surfactants during synthesis, resulting 50 	 Evidence is mounting that the low molecular-weight 
in higher organic content and a more homogeneous organic 	 region of the circulatory proteome is a rich source of diag- 
distribution in the material. However, co-condensation in 	 nostic biomarkers for the early detection of disease. In this 
one-spot synthesis also caused several difficulties in addition 	 study, a series of mesoporous silica thin films with a variety of 
to the control of the main parameters related to the EISA 	 nanophase morphologies were fabricated and comprehen- 
process. For instance, homogeneous solubility of the organic 55 sively explored their use in selective capturing and enriching 
functionalities with silicate precursor in the medium limits 	 LMW peptides and proteins from human serum. 
the selection of surface modification. In the other hand, one- 	 Different MPS thin film periodic nanostructures, formed 
spot synthesis has a limited interest in our study due to the 	 using high molecular weight triblock copolymers such as 
restricted selection of polymer templates, which must own a 	 Pluronic F127 with similar pore size distributions, can be 
different melting point than organotrialkoxysilanes. Another 60 obtained by tuning the polymer concentration in the precursor 
influencing factor is the choice of co-solvents. The participa- 	 solution. The 3D cubic and honeycomb hexagonal nano struc- 
tion of organosilane into nanostructured films may also lead 	 tures, possessing more desirable nanopore interconnectivity 
to the significant damage in the silica network. 	 and more accessible nanopore morphology, exhibit superior 
To break through the limitations aforementioned, the oxy- 	 performance in selectively enriching LMW peptides than the 
gen plasma ashing is used to treat the surface of mesoporous 65 2D hexagonal structure, even though they share similar pore 
silica chip before the post-grafting. Plasma ashing is a tech- 	 size distributions and the same molecular cut-off for serum 
nique for removing the photoresist in semiconductor manu- 	 fractionation. Precisely controlled variations in pore size can 
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be achieved through the use of copolymers with differing 
hydrophobic block lengths. The effect of pore size on the 
LMW peptide and protein recovery efficacy was investigated 
using MPS thin films prepared from four Pluronic surfactants 
(F127, P123, L64, L121, and L121 plus swelling agent) with 
different volume ratios of the hydrophilic and hydrophobic 
components to form pore sizes of 3 mu, 4 mu, 6 mu, and 7 nm 
respectively. This range of pore sizes led to the recovery of a 
different repertoire of peptides and proteins from the same 
serum sample via size and shape exclusion. Moreover, the 
conjugation of organo-silane on MPS chips has been stream-
lined by introducing oxygen plasma ashing to pre-treat the 
chip surface. Further improvement in LMWP capture and 
identification can be achieved by studying 1) the impact of 
controlling the nanotexture of the chip surface on the enrich-
ment of specific proteins, and 2) the effect of organic func-
tional groups with various charges and polarities conjugated 
within the nanoporous matrix. The individual or integral use 
of different MPS thin films with carefully tailored character-
istics provides a novel platform for the rapid and efficient 
analysis of the LMWP in human serum and may be imple-
mented for the diagnosis of disease onset in many clinical 
settings. 
Example 5.7 
Fabrication of Mesoporous Silica Thin Films 
As listed in FIG. 39, the molar ratios of starting materials 
are slightly different for various surfactants. A typical prepa-
ration of the coating sol was carried out as follows: the 
required amount of TEOS was dissolved in the mixture of 
ethanol, distilled water, and 2 M HCl and stirred for 1 hour at 
75° C. to form a clear silicate sol. Separately, a portion of 
surfactant was dissolved in ethanol by stirring at room tem-
perature. In the case of applying the swelling agent, the 
amount of PPG solution was put into the surfactant solution 
with vigorous stirring at room temperature. The coating solu-
tion was prepared by mixing the silicate sol into the triblock 
co-polymer solution followed by stirring of the resulting sol 
for 2 hrs at room temperature. The pH of the mixture solution 
remained around 1.5. The coating sol was deposited on a Si (1 
0 0) wafer by spin-coating at the spin rate of 2500 rpm for 20 
seconds. To increase the degree of polymerization of the silica 
framework in the films and to further improve their thermal 
stability, the as-deposited films were heated at 80° C. for 12 
hrs. The films were calcinated at 425° C. to remove the 
organic surfactant. The temperature was raised at a heating 
rate of I' C. per min, and the furnace was heated at 425' C. for 
5 h. The films produced were transparent and crackless. 
Example 5.8 
Chemical Modification 
Oxygen plasma ashing was performed in a Plasma Asher 
(March Plasma System) to pre-treat the MPS chip surface. 
The treatment was carried out with an 02 flow rate at 80 sccm 
and a power of 300 W for 10 minutes. Then silanate chips in 
a 3% organosilane in a Methanol:DI water (19:1) solution for 
72 hours at room temperature in N 2 glovebox. Rinse sequen-
tially with Methanol and DI water. Finally chips were cured at 
110° C. for 15 min in a fan-operated oven. 
out with a variable angle spectroscopic ellipsometer (J. A. 
Woollam Co. M-2000DI) and modeling with W VASE32 soft-
ware, the thickness of thin films and their porosities were 
measured respectively in Cauchy model and Effective 
5 Medium Approximation (EMA) model. Ellipsometric optical 
quantities, the phase (A), and amplitude (V) were carried by 
requiring spectra for 65°, 70°, and 75' incidence angels using 
wavelengths from 300 to 1800 mu. In Cauchy model, the top 
layer's thickness, reflective index, and model fit parameters 
10 A,,, B_ and C„ were determined by fitting experimental data 
with the model and minimizing the mean square error (usu-
ally less than 10). Using the EMA model, the films' porosities 
were calculated by assuming a certain volume of void in the 
pure silica and setting the top layer's thickness obtained by 
15 the Cauchy model as the constant. X-ray diffraction (XRD) 
patterns were obtained on Philips X'Pert-MPD system with 
Cu Ka ray (45 W, 40 mA). 0-20 scanning were recorded from 
all spin-coated films at Is/0.001 ° step over the angle range 
from 0.2° to 6°. Scanning transmission electron microscopy 
20 (STEM; FEI Technai; FEI Co.) was used in requiring micro-
graphs of the plant view of mesoporous silica thin films at 
high tension of 200 W. Contact angles of film surface were 
measured by goniometer with captive bubble contact angle 
measurement. Nz adsorption/desorption analysis was applied 
25 in measuring surface area and pore size distribution. Quan-
tachrome was used to record the N z adsorption/desorption 
isotherm at 77 K on the full range of relative P/P o pressures. 
Brunauer-Emmett-Teller (BET) surface areas were deter-
mined over a relative pressure range of 0.05 to 0.3. Nanopore 
30 size distributions were calculated from the desorption branch 
of the isotherms using Barrett-Joyner-Halenda (BJH) 
method. XPS spectra were recorded using a X-ray photoelec-
tron spectrometer (Kratos Axis Ultra), utilizing a monochro-
mated Al-Ka X-ray source (hv=1486.5 eV), hybrid optics 
35 (employing a magnetic and electrostatic lens simultaneously) 
and a multi-channel plate and delay line detector coupled to a 
hemispherical analyzer. The photoelectrons take off angle 
was 90°. All spectra were recorded using an aperture slot of 
300x700 microns, and high resolution spectra were collected 
40 with a pass energy of 20 eV. The pressure in the analysis 
chamber was typically 2x109 Torr during data acquisition. 
Kratos XPS analysis software was used to determine the 
stoichiometry of samples from corrected peak areas and 
employing Kratos sensitivity factors for each element of 
45 interest. 
Example 5.10 
Serum Fractionation 
50 
For each experiment, a 10 ld of serum sample was pipetted 
onto the porous surface of the wafer square. The samples were 
incubated for 30 minutes at 25 degrees (room temperature) in 
a wet chamber (100% humidity) to prevent sample evapora- 
55 tion. The samples were washed 5 times with 15 ld of sterile, 
deionized water. Peptides and proteins were eluted from the 
pores using a 1:1 (v/v) mixture of acetomtrile and 0.1% 
trifluoroacetic acid (TEA) (Sigma). 
60 	 Example 5.11 
Example 5.9 
	
Mass Spectrometry 
Characterization Techniques 	 A matrix solution of 5 mg/ml a-cyano-4-hydroxycinnamic 
65 acid (CHCA, Sigma) in a 1:1 mixture of acetonitrile and 0.1% 
	
Several characterization techniques to study the spin- 	 TEA (v/v) or a saturated solution of trans -3,5-dimethoxy-4- 
	
coated mesoporous silica thin films were studied. By carrying 	 hydroxycinnamic acid (SA, Sigma) in 2:1 mixture of aceto- 
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nitrile and water (v/v) containing 0.1% TEA was used for 	 the mixture should remain around 1.5. The final sol was 
LMW and HMW analysis respectively. Each of the samples 	 deposited on a silicon (1 0 0) waferby spin-coating at a rate of 
was mixed with the appropriate matrix in a ratio of 1:3, and 
	
1500 rpm for 20 seconds. The thickness of the film was 
spotted in duplicate onto the MALDI plate. 	 controlled by adjusting the concentration of polymer in the 
Mass spectra were acquired on a Voyager-DETM-STR 5 precursor solution, while the porosity mainly depends on the 
MALDI-TOF (Applied Biosystems, Framingham, Mass.) 	 molar ratio of polymer and silicate in the starting material. To 
mass spectrometer in liner positive-ion mode, using a 337 nm 	 increase the degree of polymerization of the silica framework 
nitrogen laser. Samples were evaluated at two m/z ranges. For 	 in the films and to further improve thermal stability, the as- 
LMW peptides and proteins, m/z of 800-10,000 Da, using 	 deposited films were placed in an oven at 80° C. for 12 hours. 
a-CHCA as matrix. Settings were optimized at an accelera-  10 For thermal calcination, the films were heated to 425' C. in air 
tion voltage 20 KV, grid voltage 19 KV, guide wire voltage 1 	 to remove the organic surfactant, at a heating rate of I' C. per 
KV, delay time 180 ns, and low-mass gate 800.300 laser shots 	 min, and the furnace was maintained at final temperature for 
crossed spot were averaged for each mass spectrum. For 	 5 hours. Afterwards the oven was cooled to room temperature 
HMW proteins, parallel analysis using SA (Sinapinic Acid) 	 over 10 hours. 
as matrix and detection range of 3,000-100,000 Da was per-  15 
formed. The instrument was optimized at acceleration volt- 	 Example 6.2 
age 25 KV, grid voltage of 23.25 KV, guide wire voltage 6.25 
KV, delay time of 500 ns and low mass gate 3,000. 	 Chemical Modification on Chip Surfaces 
The spectra were calibrated externally using the Proteo- 
Mass standards of peptides andproteins (Sigma) in eachmass 20 	 The mesoporous silica chip was pre-treated by oxygen 
range. The raw spectra were processed with the Voyager Data 	 plasma to establish a saturated hydroxyl-terminated surface. 
Explorer software version 4.0 (Applied Biosystems). 	 The treatment was performed in a Plasma Asher (March 
Plasma System) with an 02 flow rate at 80 sccm and a power 
Example 5.12 	 of 300 W for 10 min. Surface phosphorylation was carried out 
25 via immersion of the chips in 80 ml of fresh 5 mM phospho- 
Statistical Analysis 	 rous oxychloride (POC1 3, Sigma-Aldrich Co.) and 10 mM 
triethylamine (Sigma-Aldrich Co.) in acetonitrile (Fisher Sci- 
The raw spectra were processed with the Voyager Data 	 entific Co.) for 6 hr at room temperature. The chips were spun 
Explorer software version 4.0 (Applied Biosystems) and the 	 dry via spin-coater at a spin speed of 2500 rpm following by 
data was exported to SpecAlign software for pretreatment. 30 immersion overnight in aqueous solution of 5 mM Zirconium 
All spectra were aligned using the PAFFT correlation method 
	 (IV) oxychloride octahydrate/Titanium(IV) chloride (Sigma- 
and intensities were normalized to total ion current (TIC). 	 Aldrich Co.) at room temperature (see Fig. S.1). Ga 3+ was 
The peak detection was performed with a height ratio of 2 
	
immobilized on the pore surface by immersing MPS chip 35 in 
with 0.3% of the mass window, and the baseline was corrected 	 the aqueous solution of Gallium isopropoxide. The surfaces 
and the negative values were removed prior to analysis. 	 35 were rinsed with DI H 2O and spun dry at a spin speed of 3000 
Hierarchical clustering was performed using Cluster soft- 	 rpm. Finally, the chips were heated at 120° C. for 30 minutes 
ware and visualized with MapleTree software. MALDI MS 	 to remove residual water. 
Data (M/z peak intensities) were log-transformed, normal- 
ized, and median centered. Pearson correlation was used to 	 Example 6.3 
calculate the distance between the samples, and complete 40 
linkage clustering was performed. An independent Student 
	 Characterization Techniques 
t-test was used for comparison between groups (n=2 groups) 
for each detected MS peak prior to supervised hierarchical 
	 Several characterization techniques were utilized to study 
clustering analysis. A P-value of 0.02 or lower was consid- 	 the spin-coated mesoporous silica thin films. The thicknesses 
ered significant to select differentially harvested peptides and 45 of the thin films and their porosities were measured in Cauchy 
proteins among the different mesoporous proteomic chips 	 model and Effective Medium Approximation (EMA) model 
(Large pores vs. Small pores). 	 from spectra collected with a variable angle spectroscopic 
ellipsometer (7. A. Woollam Co. M-2000DI) and modeling 
Example 6 	 with WVASE32 software. Ellipsometric optical quantities, 
50 the phase (A), and amplitude (y), were acquired from spectra 
Materials and Methods 	 at incident angles of 65°, 70°, and 75° using wavelengths 
from 300 to 1800 mu. In the Cauchy model, the top layer's 
Example 6.1 	 thickness, reflective index, and model fit parameters A,,, B„ 
and C„ were determined by fitting experimental data with the 
Fabrication of Mesoporous Silica (MPS) Chips 	 55 model and minimizing the mean square error (usually less 
than 10). Using the EMA model, the film porosities were 
A typical preparation of a porous silica coating sol is as 	 calculated by assuming a certain volume of void in the pure 
follows: 14 ml of tetraethyl orthosilicate (TEOS) (Sigma- 	 silica and setting the top layer's thickness obtained by the 
Aldrich Co.) was dissolved in a mixture of 15 ml of ethanol, 	 Cauchy model as the constant. X-ray diffraction (XRD) pat- 
6.5 ml of distilled water, and 0.5 ml of 6M HCl and stirred for 60 terns were obtained on Philips X'Pert-MPD system with Cu 
2 hours at 75° C. to form a clear sol. Separately, 1.8 g of 
	
Ka ray (45 W, 40 mA). 0-20 scanning were recorded from all 
Pluronic F127 (Gifted by BASF Co.) was dissolved in 10 ml 	 spin-coated films at 1 s/0.001' step over the angle range from 
of ethanol by stirring at room temperature followed by addi- 	 0.2° to 6°. Transmission electron microscopy (TEM; FEI 
tion of 0.5 ml of DI water to form a homogeneous polymer 	 Technai; FEI Co.) was used to acquire plan view micrographs 
solution. The coating solution was prepared by mixing 7.5 ml 65 of the mesoporous silica thin films at acceleration voltage of 
of the silicate sol into the F127 solution followed by stirring 	 200 W. An EDX detector attached to the TEM was employed 
of this solution for 0.5 hours at room temperature. The pH of 	 to analyze the chemical composition of the porous surface. 
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X-ray photonic spectroscopy (XPS) were recorded using a 
X-ray photoelectron spectrometer (Kratos Axis Ultra), with a 
monochromated A,-K,, X-ray source (hv=1486.5 eV), 
hybrid optics (employing a magnetic and electrostatic lens 
simultaneously) and a multi-channel plate and delay line 
detector coupled to a hemispherical analyzer. The photoelec-
trons take off angle was 90° normal to the surface. 
Example 6.4 
Phosphoproteins Sample Preparation 
Phosvitin from egg yolk (Sigma-Aldrich Co) and a-casein 
from bovine milk (Sigma-Aldrich Co) were prepared per 
manufacture ' s instruction and 10 µg of each protein was 
trypsinized (Trypsin profile IGD kit, Sigma-Aldrich, Co) at 
37° C. overnight. Then the trypsinized proteins solution was 
split into two halves and a 10 ul of phosphatase (Sigma-
Aldrich Co) was added, followed by incubation at 30° C. for 
30 minutes. 5 µg of phosvitin and a-casein were treated with 
same procedure as mentioned above as control . For serum 
enrichment , 10 µg phosphoproteins were add into human 
serum (The University of Texas, M. D Anderson Cancer 
Center). 
Example 6.5 
On-Chip Serum Fractionation 
For each experiment , a 5 ld sample of serum or proteins 
was transferred by automatic pipette onto the porous surface 
of the chip. The samples were incubated for 30 minutes at 25° 
C. (room temperature) in a humidity chamber to prevent 
evaporation. The samples were washed 5 times with 10 ld of 
sterile, deionized water to remove surface bound material. 
Peptides and proteins were eluted from the pores using a 1:1 
(v/v) mixture of acetonitrile and 0 . 1% trifluoroacetic acid 
(TEA) (Sigma). 
Example 6.6 
Matrix Assistant Laser Deposition/Ionization Mass 
Spectrometry (MALDI MS) 
A matrix mixture (1:1) of 5 mg/ml a-cyano-4-hydroxycin-
namic acid (CHCA, Sigma) in acetonitrile (Fluke) with 0.1 % 
TEA (Sigma) was used for LMW peptide MALDI analysis. 
Each eluted sample was mixed in 2 :3 ratio with matrix and 
spotted on MALDI plate in triplicate. All peptides and small 
proteins eluted from nanopores became positively charged 
during the interaction with TEA so positive mode is used to 
detect the signals of proteins . Mass spectra were acquired on 
anAB 4700 Proteomics TOF/TOF analyzer (Applied Biosys-
tems, Framingham , Mass.) in both linear positive-ion and 
reflection modes, using 355 nm Nd-YAG laser . LMW pro-
teins and peptides with m /z of 800-10000 Da and 700-5000 
Da were selected for linear and reflection mode respectively. 
For linear mode, instrument setting was optimized at an 
acceleration voltage 20 W, grid voltage of 18.8 W, focus 
mass at 4000 Da, and low mass gate at 700. For reflector 
mode, instrument settings were optimized at an acceleration 
voltage 20 W, grid voltage of 14 W, focus mass at 2500 Da, 
and low mass gate at 700. Each spectrum was generated from 
2000 (reflection) or 5000 (linear) laser shots per sample spot. 
External calibration was performed using 4700 Calibration 
standards mix of peptides and proteins (Applied Biosystems) 
42 
in mass range of 800-10000 Da. Data Explorer software ver-
sion 4.8 (Applied Biosystems) was used to process the raw 
spectra. 
5 	 Example 6.7 
Statistical Analysis 
Processed data were imported into SpecAlign software for 
10 analysis. PAFFT correlation was used to align all spectra and 
their intensities normalized to total ion current (TIC). All 
spectra were smoothed and de-noised with factor of 4 and 0.5 
respectively. Peaks were detected with a baseline of 0.5, mass 
15 window of 21 and height ratio 1.5, negative values were 
removed before analysis. Hierarchical clustering was per-
formed using Cluster software and visualized with Maple-
Tree. MALDI MS Data (M/z peak intensities) were log-
transformed , normalized , and median centered. Pearson 
20 correlation was used to calculate the statistical distance 
between the samples, and complete linkage clustering was 
performed. An unsupervised clustering was performed for 
peaks automatically picked. 
25 	 Results 
Example 6.8 
Synthesis and Characterization of Functionalized 
30 	 MPS Chips 
By forming the layer structure of MO, octahedra, Zr 4+ and 
Ti4+ are immobilized on mesopore surface with phosphate 
terminal groups, by which each metal cation shares oxygen 
35 
atoms with monohydrogen phosphate groups, as shown 
below: 
POC13 
40 	 + 
OH OH OH 	 OH OH 	 OH 
I 	 I 	 I 	 I 	 I 	 I 
Si-0—Si-0—Si-0—Si-0—Si-0—Si-0- 
45 	 Mesopore surface 
P03H2  P03 H2  P03H2  P03H2  P03 H2  P03 H2  
0 	 0 	 0 0 	 0 
1 	 1 	 1 	 1 	 1 	 1 
—Si-0—Si-0—Si-0—Si-0—Si-0—Si-0- 
50 	 M4+ 	 M4+ 	 M4+ 
P03 
 ~~03 	 P03 	 ~~03 	 P03 ~~ 03 
1 	 1 	 1 	 1 	 1 	 1 
—Si—O—Si—O—Si—O—Si—O—Si—O—Si—O 
55 
M = Ti or Zr 
The strong coordination covalent bond between the metal 
60 ions and phosphate molecules provides a very stable and 
uniform interface of metal phosphate sites, whereby Zr 4+ or 
Ti4+ maintains activity to react with the guest molecules with 
phosphate groups. Ga" is immobilized on the pore surface by 
immersing oxygen plasma treated MPS chip in the aqueous 
65 solution of Gallium isopropoxide. Table 1 (below) list the 
ellipsometry, EDX and contact angle results of MPS chip and 
its functionalized chips. As shown, the respective thickness 
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and surface hydrophilicity are relatively unchanged despite 
the application of varied surface modifications. Their porosi-
ties decrease however due to the conjugation of different 
metal ions and acid group. Because XPS only provides the 
elemental composition on the sample surface, the EDX 
results, by profiling at greater penetration depth, show the 
lower atomic percentages of all core elements immobilized 
on the chip surface versus that measured by XPS. 
TABLE 1  
44 
C(0.282 KeV), and Cu(8.041 KeV) are seen on each of the 
displayed spectra, indicating the silica thin film and back-
ground of the TEM sample grid. More importantly, the EDX 
also detects peaks characteristic to each of the functionalizing 
metals: Ga (Ka: 9.243 KeV, Lal: 1.096 KeV), Ti (Ka: 4.508 
KeV), and Zr (Ka: 15.746 KeV, Lal: 2.042 KeV) on FIGS. 
45d, 45e, and 45f, respectively. Their atomic percentages 
have been listed in Table 1. 
The ellipsometry, EDX quantitative analysis and contact angle results 
of MPS chip and its different functionalized derivatives. 
Film thickness 	 Film 	 Atomic % of 	 Atomic % of Surface contact 
(nm) 	 porosity (%) 	 metal (EDX) 	 metal (XPS) 	 angle (°) 
MPS 	 798.20 ± 8.22 55.27 ± 0.06 	 0 	 0 	 4.90 ± 0.24 
	
MPS/Ga3± 801.97 ± 10.04 46.47 ± 0.05 Ga: 0.45 ± 0.04 	 Ga: 0.55 	 5.13 ± 0.39 
	
MPS/Ti4± 813.01 ± 13.53 43.84 ± 0.06 	 Ti: 0.55 ± 0.10 	 Ti: 1.47 	 5.93 ± 0.27 
MPS/Zr°± 	 810.11 ± 5.27 	 46.83 ± 0.03 	 Zr: 1.01 ± 0.07 	 Zr: 2.01 	 5.65 ± 0.54 
(Each result is the average number from 15 spot tests.) 
In order to confirm the successful functionalization of the 
mesoporous silica chips, elemental analysis was carried out 
using XPS for Zr4+ (FIG. 43 and b), Ti4l (FIGS. 43c and d) 
and Ga 31  (FIGS. 43e and f). As shown in FIGS. 43a, 43c and 
43e, all of the collected survey spectra show strong peaks 
corresponding to 0 is (531 eV), Si 2p (99.3 eV), and Si 2s (151 
eV); the strong peak at 981.5 eV is an oxygen Auger peak. 
Quantitative analysis of non-Auger peaks was conducted 
using high resolution spectra and reveals an oxygen-to-sili-
con ratio close to 2:1, indicative of the silica which constitutes 
our mesoporous silica thin film platform. Additionally, FIGS. 
43a, 43c and 43e contain weak C is (284.5 eV) peaks, which 
can be attributed to the presence of surface contaminants, and 
a weak P 2p (131 eV) peak, which is due to the phosphate 
group used to link the hydroxy-terminated silica surface with 
desired metal ion species. FIG. 43b shows XPS core level 
spectrum of the immobilized zirconium ion by way of a 
phosphonate chelating linker, revealing a pair of sharp, sym-
metric Zr 3d peaks. The presence of these peaks, as well as 
secondary Zr 3p peaks at 330-340 eV, confirms the presence 
of zirconium on the surface of our modified MPS chips and 
validates our conjugation method. FIGS. 43d and Of are 
high-resolution spectra of the characteristic peaks corre-
sponding to titanium (Ti 2p 112 : 464 eV, 2p 312 : 457 eV) and 
gallium (Ga 2p: 1117 eV), respectively. Gallium's presence is 
also justified by anAuger peak at 420.5 eV which can be seen 
in FIG. 43e. 
As shown in FIG. 44, calcined MPS chips templated with 
tri-block polymer F127 exhibited a well-resolved XRD pat-
tern with a sharp diffraction peak and two low intensity dif-
fraction peaks corresponding to d-spacing of 8.22, 4.10, and 
3.10 mu, respectively. These three diffraction peaks can fur-
ther be indexed as 100, 200, 210, which is a characteristic 
pattern for hexagonally arranged mesostructure. Functional-
ized MPS chips give a similar nanostructure with consistent 
cell parameters, indicating that the post-synthetic modifica-
tion by metal ions preserve the hexagonal order of nanopores. 
FIGS. 45a, 4b and 4c show TEM-obtained images of the 
metal ion immobilized MPS chips. The pores are shown to be 
uniformly distributed across the imaged area and, in accor-
dance with the obtained XRD data, present themselves in a 
hexagonal nanoporous structure. FIGS. 45d, 45e and 45f 
show EDX spectra corresponding to each of the imaged TEM 
samples. EDX peaks for Si(1.740 KeV), 0(0.523 KeV), 
Example 6.9 
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Phosphoprotein Enrichment by Mesoporous Silica 
(MPS) Chips 
The 23 kDa a-casein was used to test the effectiveness of 
the MPS chips. This protein was digested with trypsin which 
30 is a serine protease that specifically cleaves at the carboxylic 
side of lysine and arginine residues. The digestion mixture 
was then spotted on a Zr4+ immobilized mesoporous silica 
thin film, and the captured peptides were recovered for 
MALDI TOE MS analysis. Peptides in the range of 800 to 
35 4,000 Da were shown in FIG. 46. As anticipated, no peptide 
was detected from the undigested sample either in the low 
mass range (FIGS. 46a and 46d) or high mass range (10, 
000-30,000 Da). Several peaks were detected from the 
digested samples, indicating that peptides were effectively 
4o and selectively captured by the Zr4+ immobilized chip (FIG. 
46b). The amino acid sequences of the enriched phosphopep-
tides were labeled in the spectrum. In a parallel experiment, 
the trypsinized a-caseinpeptides were also treated with phos-
phatase to dephosphorylate. As shown in FIG. 46c, the same 
45 peaks in FIG. 46b could not be detected after phosphatase 
treatment, suggesting that the dephosphorylated peptides 
could not be captured by the same chip. This result further 
confirms the selectivity of the functionalized MPS chips in 
recovering phosphopeptides. Trypsin (24K Da) and phos- 
50 phatase (69 K Da) were also treated with the same protocol 
and there were no peaks detected in the spectrum, indicating 
that both enzymes were removed during the washing steps. 
Tests with Ti4' and Ga 31  immobilized chips showed similar 
results in the effectiveness of phosphopeptide enrichment 
55 (results not shown). 
To test whether phosphopeptides could also be captured 
efficiently from complex samples such as human serum, 
trypsinized phosphoprotein pho svitin was mixed with serum, 
and processed the samples with the Zr 4' immobilized MPS 
60 chips. No significant phosphopeptides were detected from 
human serum or serum mixed with undigested samples 
(FIGS. 47a, 47d and 47e). Peptides from trypsinized phos-
phoprotein phosvitin were captured and enriched by the Zr 4+ 
immobilized MPS chip (FIG. 47b), but no significant peaks 
65 were detected by MALDI TOE after dephosphorylation with 
phosphatase (FIG. 47c). The MS profiles demonstrated that 
the metal immobilized chips were able to specifically harvest 
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the phosphopeptides from complex samples, and provided a 
platform to rapidly detect LMW peptides from serum or body 
fluids. 
Example 6.10 
Hierarchical Clustering Analysis 
A hierarchical clustering analysis of peptides extracted 
from processed phosphopeptides as well as unprocessed pep-
tides was performed. As shown in FIGS. 48A, B and C, their 
columns b representing trypsinized a-casein processedby the 
functionalized MPS chips exhibited a superior enrichment of 
LMW phosphopeptides, compared to a-casein without treat-
ment or the depho sphorylated peptides. As show in FIG. 48D, 
the proteomic patterns fall into three clusters representing the 
ability of the MPS chips functionalized by Zr4+, Ga3' and 
Ti4+ to enrich phosphopeptides. The Zr4 and Ti41 chips show 
better enrichment at LMW mass range as compared to the 
Ga31 chip, which suggests that the unique coordination speci-
ficity of Zr or Ti ions immobilized on the MPS chips greatly 
improves the selectivity of phosphopeptide binding by pre-
venting acidic peptide binding. 
Example 6.11 
Conclusion 
Pho sphopeptides are present in the serum proteome at con-
centrations that require accordingly low detection thresholds 
for early biomarker identification. Various metal ions (Zr 4+ 
Ti4+ and Ga31) were immobilized on the mesoporous silica 
chips and their physico/chemical properties were fully char-
acterized. The functionalized MPS chips, with high surface 
area, large pore volume and uniform pore size distribution, 
were used to efficiently isolate and enrich the low mass phos-
phopeptides from complex human serum samples. The use of 
functionalized MPS chips with engineered binding charac-
teristics thus provides a novel platform for profiling the post-
translational modification in the human proteome and poten-
tially diagnosing early symptoms of cancer and other 
diseases. 
What is claimed: 
1. A method of analyzing a biological sample, the method 
comprising the steps of: 
a. providing the sample; 
b. providing a substrate comprising a silica-based mesopo-
rous material, wherein: 
the pores of said mesoporous material have a pre-deter-
mined pore morphology; 
a surface of the substrate is functionalized with a phos-
phate moiety to which an inorganic metal ion is 
immobilized; and 
46 
the inorganic metal ion is selected from the group con-
sisting of gallium, titanium, and zirconium; 
c. exposing the mesoporous material to the sample such 
that a fraction of the sample is retained by the mesopo-
5 	 rous material; and 
d. analyzing a fraction of the sample retained by the meso-
porous material. 
2. A method of detecting a marker of a physiological con- 
dition in a sample, the method comprising the steps of: 
to 	
a. providing a sample from a subject affected by the physi- 
ological condition; 
b. providing a substrate comprising a silica-based mesopo-
rous material, wherein: 
15 	 the pores of said mesoporous material are substantially 
uniform and have a pre-determined pore morphology; 
a surface of the substrate is functionalized with a phos-
phate moiety to which an inorganic metal ion is 
immobilized; and 
20 	 the inorganic metal ion is selected from the group con- 
sisting of gallium, titanium, and zirconium; 
c. exposing the mesoporous material to the sample; 
d. analyzing a fraction of the sample retained by the meso-
porous material; and 
25 	 e. comparing a result of the analyzing with a result of 
analyzing a control sample to detect the marker of the 
physiological condition. 
3. A probe comprising a substrate that comprises a meso-
porous material having a pre-determined morphology to 
30 
separate a first component from a second component, wherein 
said probe is configured and arranged to be inserted into a 
mass spectrometer, wherein a surface of the substrate is func-
tionalized with a phosphate moiety to which an inorganic 
metal ion is immobilized; and 
35 	 the inorganic metal ion is selected from the group consist- 
ing of gallium, titanium, and zirconium. 
4. A mesoporous silica chip comprising multiple pores, 
wherein a surface of the mesoporous silica chip is function-
alized with a phosphate moiety to which an inorganic metal 
40 ion is immobilized; and 
the inorganic metal ion is selected from the group consist-
ing of gallium, titanium, and zirconium and wherein the 
pores on said chip are of different sizes and physio-
chemical properties. 
45 	 5. The chip of claim 4, wherein said physiochemical prop- 
erties are selected from the group consisting of surface area, 
pore size, the presence of functional groups, and the presence 
of an electrical charge. 
6. The chip of claim 5, wherein said pores have a shape 
So 
comprising cubic, hexagonal, honeycomb-like, tubular, cir-
cular, oblong, and combinations thereof. 
